

DERWENT-ACC-NO: 2003-689673
DERWENT-WEEK: 200748
COPYRIGHT 2010 DERWENT INFORMATION LTD

TITLE: New N-acyl homoserine lactone acylase qsbA gene encoding a QsbA protein, useful for modulating N-acyl homoserine lactone signaling activity, or for controlling a bacterial disease in a mammal or a plant

INVENTOR: LIN Y H ; XU J L ; ZHANG L H

PATENT-ASSIGNEE: AGENCY SCI TECHNOLOGY & RES (SGST), INST MOLECULAR AGROBIOLOGY (MOLEN), LIN Y H (LINYI), XU J L (XUJLI), ZHANG L H (ZHANI)

PRIORITY-DATA: 2002W0-SG00011 (January 23, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE
<u>WO 03068951</u> <u>A1</u>	August 21, 2003	EN
<u>AU</u> <u>2002225585</u> <u>A1</u>	September 4, 2003	EN
<u>EP 1470221</u> <u>A1</u>	October 27, 2004	EN
<u>US</u> <u>20050155088</u> <u>A1</u>	July 14, 2005	EN
<u>US 7098014</u> <u>B2</u>	August 29, 2006	EN
<u>EP 1470221</u> <u>B1</u>	March 21, 2007	EN
<u>DE 60219077</u> <u>E</u>	May 3, 2007	DE
<u>DE 60219077</u> <u>T2</u>	July 12, 2007	DE

DESIGNATED-STATES: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ
DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK
LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL
TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW AT BE CH CY DE DK EA ES FI FR GB GH
GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW AL AT BE CH CY
DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR AT BE CH CY DE DK
ES FI FR GB GR IE IT LI LU MC NL PT SE TR

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
W02003068951A1	January 23, 2002	2002W0-SG00011	

AU2002225585A1	January 23, 2002	2002AU-225585	
DE 60219077E	January 23, 2002	2002DE-619077	
DE 60219077T2	January 23, 2002	2002DE-619077	
EP 1470221A1	January 23, 2002	2002EP-715955	
EP 1470221B1	January 23, 2002	2002EP-715955	
AU2002225585A1	January 23, 2002	2002W0-SG00011	
EP 1470221A1	January 23, 2002	2002W0-SG00011	
US20050155088A1	January 23, 2002	2002W0-SG00011	
US 7098014B2	January 23, 2002	2002W0-SG00011	
EP 1470221B1	January 23, 2002	2002W0-SG00011	
DE 60219077E	January 23, 2002	2002W0-SG00011	
DE 60219077T2	January 23, 2002	2002W0-SG00011	
US20050155088A1	February 28, 2005	2005US-502351	
US 7098014B2	February 28, 2005	2005US-502351	Based on

INT-CL - CURRENT:

TYPE	IPC	DATE
CIPS <u>A01</u> <u>K</u> <u>67/027</u>		20060101
CIPS <u>A01</u> <u>K</u> <u>67/027</u>		20060101
CIPS <u>A61</u> <u>K</u> <u>38/50</u>		20060101
CIPS <u>A61</u> <u>K</u> <u>38/50</u>		20060101
CIPS <u>C12</u> <u>N</u> <u>15/57</u>		20060101
CIPS <u>C12</u> <u>N</u> <u>15/57</u>		20060101
CIPS <u>C12</u> <u>N</u> <u>15/57</u>		20060101
CIPS <u>C12</u> <u>N</u> <u>15/82</u>		20060101
CIPP <u>C12</u> <u>N</u> <u>9/14</u>		20060101
CIPS <u>C12</u> <u>N</u> <u>9/18</u>		20060101
CIPP <u>C12</u> <u>N</u> <u>9/80</u>		20060101
CIPP <u>C12</u> <u>N</u> <u>9/80</u>		20060101

ABSTRACTED-PUB-NO: W0 03068951 A1
BASIC-ABSTRACT:

NOVELTY - An N-acyl homoserine lactone acylase qsbA gene and protein composition (I), comprising:

(a) a defined sequence of 3743 base pairs (bp) (N1) given in the specification, nucleotides 1234-3618 of N1, or its fragment or substantially homologous variant; or

(b) a defined peptidic sequence of 794 amino acids (P1) given in the specification, or its fragment, subunit or substantially homologous variant, encoded by the nucleic acid of (B) (respectively), is new.

DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) modulating N-acyl homoserine lactone (AHL) signaling activity, comprising contacting the AHL with the N-acyl homoserine lactone acylase qsbA protein;
- (2) a transgenic plant or non-human animal harboring a nucleic acid consisting of nucleotides 1234-3618 of the sequence of N1, or its fragment or substantially homologous variant; and
- (3) controlling a bacterial disease in a mammal or a plant, comprising administering, to the mammal or plant, the N-acyl homoserine lactone acylase qsbA protein of (I), or nucleotides 1234-3618 of the sequence of N1, or its fragment or substantially homologous variant and its peptide product (the expression of pathogenic genes of the bacteria are regulated by AHL signals).

Gene Therapy.

USE - The compositions (I), nucleic acids and proteins are useful for modulating N-acyl homoserine lactone signaling activity, or for controlling a bacterial disease in a mammal or a plant.

ABSTRACTED-PUB-NO: WO 03068951 A1
EQUIVALENT-ABSTRACTS:

BIOTECHNOLOGY

Preferred Composition: The composition of matter may also comprise a peptidic sequence comprising amino acids 36-271 or 233-794 of the sequence of P1. The composition of matter inactivates N-acyl homoserine lactone.

Preferred Method: In controlling a bacterial disease in a mammal, the mammal is preferably a human. Alternatively, controlling a bacterial disease in a plant comprises using any bacterial species containing the (I) comprising nucleotides 1234-3618 of the sequence of N1, or its fragment or substantially homologous variant.

Preparation: The nucleic acids and proteins of (I) may be produced via standard methodologies.

SPECIFIC GENES

N-acyl homoserine lactone (AHL) acylase genes from *Ralstonia* sp. XJ12B, termed qsbA genes, which encode QsbA proteins possessing AHL inactivating activity, are claimed.

A bacterial biofilm sample was collected from a water treatment system and screened to isolate N-acyl homoserine lactone (AHL) inactivation bacterial strains. Two bacterial isolates from the biofilm sample with distinct phenotypes, XJ12B and XJ12A, were found to possess the ability to inactivate AHL, with XJ12B showing stronger enzyme activity. A cosmid library of 1600 clones was constructed in *Escherichia coli* with the genomic DNA of *Ralstonia* sp. strain XJ12B. The *E. coli* transfectants were screened for AHL inactivation activity using oxo-octanoyl-L-homoserine lactone (OOHL) as the substrate. Only a single clone (p13H10) was identified as showing AHL inactivation activity. To subclone the gene encoding the detected activity, cosmid DNA from the positive clone p13H10 was partially digested with *Sau*3A and fused into *Bam*HI digested cloning vector pGEM-3Zf+. The plasmids were ligated and transformed into *E. coli*, and the *E. coli* were assayed for the ability to inactivate AHL. Clone

p2B10, which contains a 4-kb insert, had AHL inactivation activity. The plasmid clone p2B10 containing the qsbA gene was used as a template. The 4-kb fragment from clone p2B10 was completely sequenced showing a sequence of 3743 bp fully defined in the specification. The longest open reading frame encodes 794 amino acids fully defined in the specification, with a predicted molecular weight of 85373 Daltons.

DERWENT-CLASS: B04 C06 D16 P13 P14

CPI-CODES: B04-C01G; B04-E02F; B04-E03F; B04-N04A0E; B04-P0100E; B14-A01;
B14-S03; C04-A0800E; C04-C01G; C04-E02F; C04-E03F; C04-N04A0E; C04-P0100E;
C14-A01; C14-S03; D05-H12A; D05-H16A; D05-H16B; D05-H18;

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 August 2003 (21.08.2003)

PCT

(10) International Publication Number
WO 03/068951 A1

(51) International Patent Classification⁷: **C12N 9/80**,
15/57, A01K 67/027, A61K 38/50

[AU/SG]; 360 Pasir Panjang Road, #04-10 Goldcoast
Condominium, 118699 Singapore (SG). **XU, Jin, Ling**
[AU/SG]; 360 Pasir Panjang Road, #03-11 Goldcoast
Condominium, Singapore 118699 (SG).

(21) International Application Number: PCT/SG02/00011

(22) International Filing Date: 23 January 2002 (23.01.2002)

(74) Agent: **ELLA CHEONG MIRANDAH & SPRUSONS**;
Robinson Road Post Office, P.O. Box 1531, Singapore
903031 (SG).

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **INSTITUTE OF MOLECULAR AGROBIOLOGY** [SG/SG];
1 Research Link, National University of Singapore, Singapore 117604 (SG).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHANG, Lian, Hui** [AU/SG]; 360 Pasir Panjang Road,, #03-11Goldcoast Condominium, Singapore 118699 (SG). **LIN, Yi, Han**


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: RALSTONIA AHL-ACYLASE GENE



(57) Abstract: This invention provides a gene, *qsba*, which encodes a protein useful for inactivating certain bacterial quorumsensing signal molecules (N-acyl homoserine lactones) which participate in bacterial virulence and biofilm differentiation pathways. This gene was isolated from *Ralstonia sp.*, strain XJ12B. The invention also provides the QsbA protein, which possesses N-acyl homoserine lactone inactivating activity.



WO 03/068951 A1



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

RALSTONIA AHL-ACYLASE GENE

BACKGROUND OF THE INVENTION

Field of the Invention

[0001] This invention pertains to the field of molecular biology. In particular, the invention relates to an N-acyl homoserine lactone acylase gene from *Ralstonia* sp. XJ12B.

Description of the Background Art

[0002] N-acyl homoserine lactones (AHLs), also known as autoinducers, are widely used quorum sensing signal molecules in many Gram-negative bacteria. These compounds regulate certain classes of target genes in bacteria, such as virulence genes or biofilm differentiation genes. Generally, quorum sensing molecules are highly conserved and share an identical homoserine lactone moiety. The length and structure of their acyl side chains are different, however. Although the target genes regulated by AHLs in different bacteria species are varied, basic mechanisms of AHL biosynthesis and gene regulation are conserved among different bacterial species.

[0003] The general feature of AHL-mediated gene regulation is that it is cell population dependent (quorum sensing). Bacteria secrete AHLs into the environment; extracellular concentration of AHLs increases as bacterial cell populations grow. When AHL accumulates to a threshold extracellular concentration, the expression of certain sets of target genes are triggered in the bacteria.

[0004] Bacteria using these signals release, detect and respond to the accumulation of AHL signal molecules for synchronizing expression of a particular sets of genes and coordinating cellular activities within the bacterial cell population. AHLs are involved in regulation of a range of biological functions, including bioluminescence in *Vibrio* species (13, 4), Ti plasmid

conjugal transfer in *Agrobacterium tumefaciens* (31), induction of virulence genes in *Burkholderia cepacia*, *Erwinia carotovora*, *Erw. chrysanthemi*, *Erw. stewartii*, *Pseudomonas aeruginosa*, and *Xenorhabdus nematophilus* (3, 6, 12, 17, 19, 22, 23, 24, 26), regulation of antibiotic production in *P. aureofaciens* and *Erw. carotovora* (6, 26), swarming motility in *Serratia liquifaciens* (14) and biofilm formation in *P. fluorescens* and *P. aeruginosa* (1, 8). In many other bacterial species the relevant biological functions controlled by AHLs remain to be investigated (2, 5, 11).

[0005] A number of plant, animal and human bacterial pathogens use AHL quorum-sensing signals to regulate expression of pathogenic genes and aid in the formation of biofilms. Therefore, AHL quorum-sensing signal molecules are group of molecular targets for genetic and chemical manipulations since disruption of these signaling mechanisms can prevent or reduce the ability of these bacteria to infect plant and animal tissues or to form biofilms.

[0006] The gene encoding an AHL-inactivation enzyme (AiiA) from a Gram-positive bacterium (*Bacillus* strain 240B1) has been cloned (9). AiiA (also known as AHL-lactonase) inactivates AHL activity by hydrolyzing the lactone bond of AHLs (10). Expression of *aiiA* in transformed *Erw. carotovora* (a pathogenic strain which causes soft rot disease in many plants) significantly reduces the release of AHL, decreases extracellular pectrolytic enzyme activities, and attenuates pathogenicity on potato, eggplant, Chinese cabbage, carrot, celery, cauliflower, and tobacco (9). Transgenic plants expressing AHL-lactonase showed a significantly enhanced resistance to *Erw. carotovora* infection and delayed development of soft rot symptoms (10). AHL-inactivation mechanisms appear to be widely distributed. For example, a bacterial isolate of *Variovorax paradoxus* was reported to use AHL molecules as its energy and nitrogen sources, indicating the possible presence of AHL-degrading enzymes (18).

[0007] Further methods to counteract AHL-mediated plant, animal and human disease and plant pathogen virulence by interfering with bacterial intercellular communication would be highly desirable.

SUMMARY OF THE INVENTION

[0008] Accordingly, in this study, the cloning and characterization of a gene encoding an AHL-acylase from a bacterial isolate *Ralstonia* sp. JX12B is reported.

[0009] In one embodiment, the invention provides a composition of matter which comprises a nucleic acid according to SEQ ID NO: 1. In another embodiment, the invention provides a composition of matter which comprises a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.

[00010] In yet a further embodiment, the invention provides a nucleic acid according to claim 2 which comprises nucleotides 1234-3618 of SEQ ID NO: 1.

[00011] In yet a further embodiment, the invention provides a composition of matter which comprises a peptidic sequence selected from the group consisting of a peptidic sequence according to SEQ ID NO: 2, a fragment thereof and a substantially homologous variant thereof.

[00012] In yet a further embodiment, the invention provides a composition of matter which comprises a peptidic sequence encoded by a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.

[00013] In yet a further embodiment, the invention provides a composition of matter which comprises a peptidic sequence selected from the group consisting of SEQ ID NO: 2, a fragment thereof, a subunit thereof and a substantially homologous variant thereof, such as a peptidic sequence according to SEQ ID NO: 2, a peptidic sequence comprising amino acids 36-217 233-794[?] of SEQ ID NO: 2 or a peptidic sequence comprising amino acids 233-794 of SEQ ID NO: 2.

[00014] In yet a further embodiment, the invention provides a composition of matter as described above which inactivates AHL.

[00015] In yet a further embodiment, the invention provides a method of modulating AHL signaling activity which comprises contacting said AHL with a composition of matter as described above.

[00016] In yet a further embodiment, the invention provides a transgenic plant or non-human mammal harboring a nucleic acid as described above.

[00017] In yet a further embodiment, the invention provides a method of controlling a bacterial disease in a mammal which comprises administering to said mammal a composition of matter as described above, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

[00018] In yet a further embodiment, the invention provides a method of controlling a bacterial disease in a plant which comprises administering to said plant a composition of matter as described above, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

BRIEF DESCRIPTION OF THE DRAWINGS

[00019] Figure 1 is a photograph showing AHL inactivation bioassay results for bacterial cultures and bacterial proteins from the indicated bacterial clones. Figure 1A shows the results of a bioassay with bacterial cultures of *E. coli* DH5 α strains 13H10 (slice 1), 2B10 (slice 2), MUB3 (slice 3), MUC6 (slice 4), GST-QsbA (slice 5) and GST (slice 6), which contain plasmid clones or constructs p13H10, p2B10, pMUB3, pMUC6, pGST-QsbA, and pGST, respectively. Figure 1B shows results for bioassay of the indicated bacterial proteins GST-QsbA and GST.

[00020] Figure 2 is a graph showing the temperature and pH optimum profiles of AHL acylase.

[00021] Figure 3 is a graph showing the time course of OOHL inactivation by the purified AHL-acylase.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[00022] A bacterial isolate of *Ralstonia* sp. XJ12B from a biofilm sample in a water treatment system was found to enzymatically inactivate AHLs, bacterial quorum-sensing molecules, in a bioassay using *Agrobacterium tumefaciens* strain Nt1 (*traR*; *tra::lacZ749*) as an indicator for AHL activity. The gene encoding the protein exhibiting this enzyme activity for AHL inactivation (*qsba*) was cloned from a bacterial strain isolated from the biofilm sample and found to encode a peptide of 794 amino acids.

[00023] Bacterial cultures and bacterial proteins were assayed for the ability to inactivate AHL using *Agrobacterium tumefaciens* indicator cells. A *tumefaciens* was cultured at 28°C in MM medium as described in Zhang et al. (31). The bacteria or protein to be assayed is first mixed with an AHL substrate, for example N- β -oxooctanoyl-L-homoserine lactone (OOHL), and the reaction (inactivation of the AHL) is allowed to proceed. If AHL inactivation activity is present in the sample (*i.e.* the AHL has been cleaved and inactivated), then the inactivated AHL products fail to trigger the expression of *lacZ* reporter gene which is under the control of a TraR-dependent promoter. The strain *A. Tumefaciens* NT1 hosting the *lacZ* reporter system therefore does not turn blue in the presence of substrate 5-bromo-4-chloro-3-indolyl β -D-galactopyranoside (X-gal). See Example 2 for details of the bioassay. Any AHL may be used in the assay, as desired. Of course, any suitable assay for cleavage of AHL, including traditional *in vitro* enzyme assays may be used to detect the AHL inactivation activity. Those of skill in the art are able to modify or devise assays to detect and/or quantitate AHL inactivation.

[00024] *Escherichia coli* strain DH5a was used as a host for DNA manipulation. Both *Ralstonia* sp. and *E. coli* were cultured in LB medium (tryptone, 10 g/L, yeast extract, 5 g/L, and NaCl, 10 g/L, pH 7.0) at 37°C. Appropriate antibiotics were added when necessary at the following concentrations: ampicillin, 100 μ g/ml; tetracycline, 10 μ g/ml; and kanamycin, 20 μ g/ml.

[00025] The gene encoding the protein responsible for the detected AHL inactivation was isolated using a cosmid library of 1600 clones with the genomic DNA of *Ralstonia* sp. strain XJ12B, constructed in *E. coli*. *E. coli* transfectants were screened for the ability to inactivate AHL. One clone, p13H10, was found to inactivate AHL. Cosmid DNA from p13H10 was digested, fused into a cloning vector, ligated and transformed into *E. coli*. The *E. coli* clones again were assayed for AHL inactivating activity. One clone, containing a 4 kb insert, had AHL inactivation activity.

[00026] Plasmids were subsequently purified for sequencing. The 4 kb fragment from clone p2B10 was completely sequenced according to known methods using ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Applied Biosystems). See Table I, below. The sequence contained an open reading frame of 2385 nucleotides which was the AHL inactivation gene, *qsba*, encoding a predicted polypeptide of 794 amino acids (85,373 Daltons).

Table I. *QsbA* Gene (*Ralstonia* sp.) Nucleotide Sequence (SEQ ID NO: 1).

```

gtttggaaagtgggnagcgcgtgtgcag cgcgccgccccctcagccgcgcagctcgccg cgcaccgaatgcgcgcgcgggtgggcgcgc 90
ggcggctggccggtgtggcgcggatcagg cgcgggaaggcggacatgtcgtgataaccg cactgttcggcgattgccgtcaggctcagc 180
gtgctgactttccagcaggtggcaggcgcg tccacgcgcagccggtgcagcaattgcagc ggcgaggtgccagggctcttggtgaaatgc 270
cgcagcagcgtgcgctcgtgtggtcgaggcg gggcgccagcttggccaggtcgaaaggc tcgtgcaggtgctgctcaggttagcgcgc 360
gcccgagtagccacgctggtgcggatggcg ggcttgcgtgcgcagccagatggcggtggac tcaccgcgcgacgggtggtgcagcaggcc 450
tggccgaggggtgcgtgccagccgggtgtcg gccaggcgccgaccagcgctgcgtgagc gccacgcccgtgctccatcgcgccgcgctc 540
agcacgttgccgctgctgacgatggcctgc tccgccaccaccttcagctgcgggtagtgc ccgtgcagccagccggcgatcagccacgtc 630
accgtcaagcgcggcgccggcgaggcgcg cggccagcagcgccacgcccgtgaaggac gaggccaccaagcctgcccgcgtccaggta 720
gcgcggatggtggcgcggttcccactccag caggccaggcgctgctccagcgtgctgat gtggtcgaaatgcagggggcgagaccag 810
cgcgtcgcacagcgcggcgctgcccccgcg cagcggtgcgcagcgccagggcagggtctc ggccggcgccctgccagcgggcggtgcgc 900
cgcgaccagcgcacccgaacacggggtgt ggcggcatcggcacgcttgccggcatgcat ggagcgagcgcatggccacgcggagggt 990
gtcgcgacgggtgcgcagcgtggagagggc ggcgtcggaagggtcagcaggtcgatgtc ggcacccgcaagtagggggagggcg 1080
gagggcctcctgcgtggcggtattgacccca actctggcggaatacctcttctccggg cggggcccgatcgacgatacggcggtggt 1170
gcgcctgcgcgcggcgcaagactagagcg acacaagacaagaccgacaaggagacaa cgcATGATGCAGGGATTCGCGCTGCGCGGC 1260
ACGCTCGCCATGGCCGCGCTCGCGCGCTG GCCGCTGCGCCAGTTCCACCGATGGCCGC TGGGGTTCGCTCAGCGACACCGGCTGTCC 1350
GCCGAGATCCGCGCACCGGCTTCGCGCAT CCGACATCCGCGCAACGACTACGCCAGC CTCGGCTATGGCATGGCCTATGCCATCGCG 1440
CAGGACAACCTGTGCCGTGCTGGCCGACAG GTGGTCAACCGTCAACGGCGAGCGCTCGAAG ACCTTCGGGCGCAGGGCAGCGTACCGGTC 1530
TCGTTCAAGCCGATCCCCAACCTGCAGTCG GACGCTTCTTCAAGGGCATCTTCGACGAG GACGGCTGCGCGCCGGTTATGCGCAGATG 1620
TCGCCCCAGGCGCGCGAGCTGCTCGCGGGC TACATCGCCGGCTTCAACCGCTATCTCAAG GACACGCCGCCGCCAACTTCCCGGCCGCC 1710
TGCCGCAATGCCGCTTGGGTGCGTCCGCTC ACCTTGGGCGCATGTGCGCATGGGCGGAA GAGAAGGCGATTCAGGCGCAGCGCCGCGCC 1800
ATGCTGCGCGGATCGTTCGCGCGCAGCCG CCGGCGCGCAGCGCGGTGGCGCAGCGCGAG ATTCCGCGCAGGCGCTCGACACCGTGGCG 1890
CTGGACCGCGAAGTGCAGCTGCGCGACATG CCGATCGGCTCCACGGCTGGGCTTCGCGC GCTGACGCCACCGCAACCGGCGCGCGCTG 1980
TCGCTCGGCAATTCGCGCACTTCCCCTGGAC ACCACCAACCGCTTCTACAGGTCCACCTG ACGGTGCGCGCAAGCTCGACGTGATGGGC 2070
GCCTCGATCGCGGCTTCCCCTGGTGGTGAAC ATCGGCTTCAACAAGGACGTGGCGTGGACG CACACCGTCTCCACCGGCGCGCGCTTCAC 2160
TTGTTCAAGTGAAGTGGCCGAAGCGGAC CCGACCCTTACCTGGTTCGACGGCAGCGCG CGCACCTTACCTTCTACGACACCATC 2250
GACGTGAAGCTGCCGCGCGCGGCTCGAG GCGCGCACGACACCTTCTACGACACCATC TACGCGCGGTGCTGTCGATGCCGAGCGGC 2340
GGCATGCCGTGGACACGCAAGGCTTAC GCGCTGCGCGACGCCAACCGCAACACAG CGCTCGGTTCGACAGCTGGCTGCATTCGGG 2430
CAGGCCCCGGGACGTGGCGCGCATCCGCGC GGCATCGGCAACCTGGGCTTCCCTGGGTC AACACCATCGCCACCGACCGCAACGCGCC 2520
GCGCTGTTCCGCGACGTGTCGACACGCGG GACGTCCCGCGCGGAGCTCCAGCGCTGT GCCCGCTGCGCGCTGGCGCGCAACTCTTC 2610
AAGGACCGCGGCTGCTGCTGCTCGACGGC TCGCGCGGCACTGCAACTGGCAGGTTCGAT CCGGCTTCGCGGTTACCGGGCTGGTGGCG 2700
CCGCGCGCATCCCGGTGCTCGAGCGCGAC GACTACGTGCGCAACGCAATGACAGCTCC TGGCTGACCAACCCCGCGCAAGCTGACC 2790
GGCTTCTCGCGGCTGATGGGCTCGGTCGAC GTACCGCAGCGGCTGCGCAGCGCATCGGC CTGCCGAACCTGCAGCGGATGATCTTCAGC 2880
ACCGACGGACTGCCCGCAACCGCATCGAT CTGCCGAACCTGCAGCGGATGATCTTCAGC AATGCCAACCTGGCGGGCAACTGGTGTCT 2970
GGCGACCTGCTCGCGGATGCAAGGCCACG CCGGCGCGGATGCGGATGCGCGAGCGGC TCGCGCGCCCTCGGCGAGTGAACCGCACC 3060
AGCAACCGCGACGCGCGCGCGCGCACTG TTCCGCGAGTTCTGGATGCGCGCGCAAGGAC ATCGCGCAGGTGCACGCCCTCGAGTTCGAC 3150
CCGCGCGACCGGTGACACGCGCGCGCGG CTGCGCATGAACGACGCGGATACGCAAG GCGGTGTTCAAGCGGCTGAAGGAAGCGCTG 3240
GGCGCGGTGCGCAAGGCGGGCTTCGCGCTG GATGCGCGCTGGGCGAGGTACAGGCGCGG CACGACCGGACGGCTCCATCGCCCTGCAC 3330
GGCGCGGAGGAATACGAAGGCTGCTCAAC AAGTGCACAACTTCGCGATCGGCGCGAAG GGGCTGCGCGGTGATTTTCGCGACCGACT 3420
ATCGACCGGTGACCTTCGACGACGAGGCG CCGGTGCGCGACGCGCATCTCACTACGGC GAATCGACCGACCGCTCGCGCGACGCG 3510
TTCGACCGAGATGCGTGTCTACTCGGCAAG CACTGGAACCGGCTGCGGTTCTCCGAAGC GCCATCGCGCGGATCGGCGCTGAAGGTG 3600
ATCGGTTGTCGCGAGTGAAGggtgctgggtg cctggaaaaacgccccgcttgcgcggggcg ttttttgcagtgatgaatggtcgaatcgt 3690
gttgaaaccgcatccggacatgactgtat tgtgactctgcctgtgtccgtgt 3743

```

The predicted open reading frame of the *qsbA* gene is shown in upper case letters with the start codon and stop codon in bold. A putative ribosome binding site (AGGAGA) is underlined.

[00027] Sequence analysis of this peptide indicated that *QsbA* did not have any significant homology with the known AHL-lactonase quorum-sensing molecule inactivator encoded by the *aiiA* gene from *Bacillus* sp. 240B1, however the deduced peptide sequence was typical of the primary structure of aculeacin A acylases (AACs) and penicillin G acylases, with signal peptide- α subunit-spacer- β subunit organization (16, 30). The *Ralstonia* sequence shares substantial identity with AACs from *Deinococcus radiodurans* strain R1, *Actinoplanes utahensis* and a putative acylase from *Pseudomonas aeruginosa*, all of which catalyze deacylation of their substrates. These AAC genes are translated as single precursor polypeptide and then processed to the active

form, which has two subunits. Aculeacin A is an echinocandin-type antifungal antibiotic with a long fatty side chain. Aculeacin A acylases purified from *A. utahensis* catalyze the hydrolysis of the amide bond on the palmitoyl side chain of aculeacin A (29). The primary structure of the protein, as well as enzyme activity analysis with different substrates, discussed below, therefore indicates that *qsbA* encodes an AHL-acylase which cleaves the amide linkage between the acyl side chain and the homoserine lactone moiety of AHLs.

[00028] The presumed α and β subunits of QsbA are located at amino acid positions 36-217 and 233-794, respectively, of SEQ ID NO: 2, with a 15 amino acid spacer between them, as determined by alignment with the peptide sequences from *D. radiodurans* strain R1, *A. utahensis* and *P. Aeruginosa*. See Table II.

Table II. Aligned Amino Acid Sequences of *QsbA* from *Ralstonia* sp. XJ12B (SEQ ID NO: 2), *D. radiodurans* strain R1 acylase (SEQ ID NO: 3), *A. utahensis* acylase (SEQ ID NO: 4) and *P. aeruginosa* acylase (SEQ ID NO: 5).

R.sp	MMQGF---ALRGTLAMAALAALAGCA-----SSTDGRWGSLSDTGLSAEIRRTGFGIPHIRANDYASLGYGMAIYAQDN	72
D.rad	MSR-----SPFSSVSLPARLLLSLL-----LGPLMLGGAASAQTYQVQIQRTAHGIPHIQASDLGGIGYGVGYSAQDN	70
A.uta	MTSSY---MRLKAAAIAGFVIVATAA-----VPSPAS-GREHDGGYAALIRRASVGVPHITADDFGSLGFGVGYVQAEDN	71
P.aer	MSRPFPPPLCRETTSNGMRTVLTGLAGMLLGSMMFPVQADMPRETGLAADIRWTAYGVPHIRAKDERGLGYGIGYAYARDN	80
	* : : : : . . *: :.*:*** *.* .*:*:.* **	
	1	
R.sp	LCLLADQVVTNNGERSKTFEGEFTVTVSFKPIPNLQSDAFFKGFDEDEGLRAGYAQMSPEARELLRGYIAGFNRYLKDTP	152
D.rad	LCLLADQVMTVRGERSKFLCAEGKTVVGFQPVNNLSDVFFKTVIEPGRQLQAGYRDQ-PQILALMRGVVAGVNNRYLRDTP	149
A.uta	ICVIAESVVTANGERSRWFGATGPDADVRTTSSTQAIIDRVAERLLEGPRDGVRAPCDDVRDQMRGEFVAGYNHFLRRTG	151
P.aer	ACLLAEEIVTARGERARYFGSEGKSSAELD---NLPSDIFYAWLNQPEALQAFWQAQTPAVRQLLEGYAAGFNRLREAD	157
	:.*:*.**:*:.* :	
R.sp	PANFP-AACRNAAWVRPLTLGDMMRMGEEKAIQASAGAMLAGIVAAQPPGRTPVAEREIPPQAVDTVALDRELQLRDMPI	231
D.rad	PEQWP-SACRNADWVRPLTELDVMRLGEEKAIQASAGAMVSAITSAREPPQ---AGASTAAPRPDLAAFNRYRFDNLPI	224
A.uta	VHRLTDPACRGKAWVRPLSEIDLWRTSWDSMVWAGSGALLDGIVAATPPT---AAGPASAPEAPDAAAIAAALDGTSGI	228
P.aer	GKTTS---CLGQPWLRATDLDLLRLRLRLVLEGGVGFADALVAAAPPQ---AEKVALSGEQAFQVAEQRRQRFLER	230
	. * . *:*.*: * : * :... * : .*:.* ** *	
	↑	
R.sp	GSNGWAFGADATANRRGVLLGNPHFPWTTNRFYQVHLTVPGKLDVMGASIAAFPVVSIGFNKDVAWHTVSTGRRFTLF	311
D.rad	GSNGWAFGSEATTNGRGLLLGNPHFPWETSNRFYQLHLTLPGQFDVMGASLGGMPVVNIGFNQDVAWHTVSTDKRFTLA	284
A.uta	GSNAYGLGAQATVNGSGMVLNPHFPWQGAERFYRMHLKVPGRYDVEGAALIGDPIIEIGHNRTVAWSHTVSTARRFVWH	288
P.aer	GSNAIAGVGSERSADGKGMILLNPHFPWNGAMRFYQMHLLTIPGRLDVMGASLPLPVVNIGFSRHLAWHTVDTSSHFTLY	290
	. .*: : : *:*.** : ***:**:*: ** ***: . *:*.***. :*:***. *	

```

R.sp      ELKLAEGDPTTYLVDGTPHKMTTRTVAFDVKLPDGRLERRTHTFYDTIYGPVLSMPSGGMPWTTQKAYALRDANRNNTRS 391
D.rad     ALTLVPGDPLSYVKDGGQRRRLQRRRTAVIEVKTANG-PRLHTRTVYFTPEGPLVNLPAAGLTWTPQYAFALRDANRNNTRM 383
A.uta     RLSLVPGDPTSYIYVDGRPERMRARTVTVQTGSG-----PVSRTFHDTRYGPVAVVP-GTFDWTTPATAYAITDVNAGNNRA 383
P.aer     RLALDPKDPRLYLVDGRSLPLEEKSVAIEVRGADGKLSRVEHKVYQSIYGPLVVWP-GKLDWNRSEAYALRDANLENTRV 390
          * *   ** *   **   :   :...:.   :...:   **:   *   .   :   *   *::: *.*   *.*

R.sp      VDSWLHIGQARDVAGIRQAIG-NLGIPWVNTIATDRNGRALFADVSTTPDVPAELQRCAPSPLAGKLFKDGAVLLDGS 470
D.rad     LATWLGFAGAKSVRDIRASLN-VQIGIPWVNTIAADRAGSALYADISSSPNVSAQQQACTPPPLA-PLFPAAGLAVLDGS 461
A.uta     FDGWLRMGQAKDVRALKAVLDRHQFLPWVNVIAADARGEALYGDHSVVPRTGALAAACIPAPFQ-PLYASSGQAVLDGS 461
P.aer     LQQWYSINQASDVADLRRRVEALQGIPWVNTLAADDEQGNALYMNQSVVPYLKPELIPACAIQQLV-----AEGLPALQGG 464
          .   *   :   *   . *   ::   :   :****.:*: *   ***:   : *   *   :   *   .   :   *   *:::

R.sp      RGTCNWQVDPASPVPLVAPFARMVLERDDYVANSNDSSWLTPAQKLTGFSFVPMGSVDVPQRLRTRIGLIEIGRRLAGT 550
D.rad     HSACDWKTDPASRVPLRAPDKMPVLIRQDFVANSNNSAWLANPAPQTGLDPLVGEVNPAPQSPRTRMGLLEIGRRLSGT 541
A.uta     RSDCALGADPDAAVPGILGPASLPVRFRDDYVTSNDSHWLASPAAPLEGFPRLGNERTPRSLRTRLGLDQIQRLAGT 541
P.aer     DSRCAWSRDPAAQAAGITPAAQLPVLLRRDFVQNSNDSAWLTNPASPLQGFSPVLSQE-KPIGPRARYALSRLQKGQP-- 543
          .   *   **   :   .*:   .   :** *   *:*   ***: *   **   *   :   :...

R.sp      DGLPGNRIDLPNLQAMIFSNANLAGQLVLGDLAACKATPAPDAD-----VRDGCAALGQWNRTSNADA-RAAHLFREEF 630
D.rad     DGLPGRTFDIPTLQATLLRESNLTGEMYAADAAKLCQS--AGGAE-----LQPACNALAAWDRSSQES-RGAALWREF 619
A.uta     DGLPGKGFTTARLWQVMFGNRMHGAELVRDDLVALCRRQPTATASNGAIVDLTA ACTALS RFDERADLDS-RGAHLFTEF 621
P.aer     -----LEAKTLEEMVTANHVFSADQVLPLDLLRLCRDN-QGEKS-----LARACAALAQWDRGANLDSGSGFVYFQRF 613
          :   *   :   :   .:   *   *:   .   :   . *   **   .:   .:   .:   .   .:   *

R.sp      WMRAKDIAQVHAVEFDPADPVHTPRGLR-MNDATVRTAVFKALKEAVGAVRKAGFALDAPLGTVQAAHAPDGSIALHGGE 702
D.rad     WRRARAI PNVIYAVFPDPADPVNTPRGLN-TADPAAQTALLGALREAAAALTAAGIPFDAPLGEVQGVVRGDDFISLPGGA 691
A.uta     LAGG----IRFADTFEVTDPVRTAPFVNTTDPVRVRLADACNGSPASPSTR-----SVGDIHTDSRGERRIPHGG 690
P.aer     MQRFAELDGAWKEPFDAQRPLDTPQGIA-LDRPQVATQVRQALADAAAEEVEKSGIPD GARWGD LQVSTRGQERIAIPGGD 686
          *:   *:   **   :   .   . *   :   *   .   .   *   :   *   :   *:   **

R.sp      EYEGVLNKLQTLPIGPKGLPVYFG--TSYIQTVTFDQGPVADAILTYGESTDHASPHAFDQMRAYSGKHWNRLPFSEAA 780
D.rad     EFEGVLDKIDFNPLAPGGYRGVGNASSYIQTVGFTDSGVQAEAVLTYSQSSNPESPYFSDQTRLFSRSEWVKLPFTQPE 771
A.uta     GEAGTFNVITNPLVPGVGPQVVG--TSFVMAVELGPHGPSGRQILTYAQSTNPNSPWYADQTVLYSRKGWDTIKYTEAQ 769
P.aer     GHGFVYNAIQS--VRKGDHLEVVG--TSYIQLVTFPEEGPKARGLLAFSQSSDPRSPHYRDQTELF SRQQWQTLFSDRQ 763
          *.   .:   :   :   .   .   :*:   *   :   *   .   :*:   .:   **   **   :*   . *   :   ::

R.sp      IAADPALKVMRLSQ--- 794
D.rad     IEADPTRTVVQLSE--- 785
A.uta     IAADPNLRVYRVAQRGR 786
P.aer     IDADPQLQRLSIRE--- 777
          *   ***   :   :

```

* = identical residues, : = conserved substitutions; . = semi-conserved substitutions; ! = post-translational processing sites for signal peptide and subunits; - = spacers.

[00029] The coding region of the *gsbA* gene was amplified by PCR. The amplified PCR products were digested, fused in-frame to the coding sequence of the glutathione S-transferase (GST) gene and expressed in *E. coli*. Protein extracts from the recombinant *E. coli* cells were assayed for the ability to inactivate AHL. Protein from *E. coli* expressing GST alone

served as a control. The results demonstrated that GST-QsbA fusion protein effectively eliminated AHL activity. See Figure 1B.

[00030] The substrate specificity of QsbA was determined by assaying total soluble protein extracted from the recombinant *E. coli* (pGST-QsbA) for inactivation of AHLs using substrates with acyl chains of differing lengths. QsbA was able to completely inactivate 3-oxo group acyl-HSLs having acyl chains of 8, 10 and 12 carbons. QsbA also strongly inactivated methylene group acyl-HSLs having acyl chains of 8 and 10 carbons. QsbA also inactivated the butyl and hexyl esters of N- β -octanoyl-L-homoserine, whereas the AHL-lactonase encoded by *aiiA* was unable to inactivate them. The substrate specificity data indicate that QsbA is an AHL-acylase.

[00031] QsbA and *qsbA* provide new tools for down regulation of AHL-mediated biological activities, such as the expression of virulence genes and biofilm differentiation in pathogenic bacteria, both *in vitro* and *in vivo*. The *qsbA* gene, which encodes the AHL inactivation enzyme (QsbA), or a functional fragment, subunit or substantially homologous variant thereof, may be introduced into a plant genome to produce a genetically modified plant with the ability to quench pathogen quorum-sensing signaling. Transgenic plants expressing an enzyme that inactivates AHLs can exhibit a significantly enhanced resistance to infection by bacterial pathogens, even when bacteria are present in high concentrations.

[00032] Methods of genetic manipulation and transformation of plant cells are well known in the art, as are methods of regenerating fertile, viable transformed plants. In general, any method of cloning the coding region of *qsbA* or a functional fragment or substantially homologous variant thereof into a suitable expression vector may be used. It is convenient to ligate the *qsbA* coding region into a vector, followed by ligation into a plant transformation vector, however those of skill are well aware of alternative methods to achieve the same results. Any suitable plant transformation vector may be used.

The vector contains the *qsbA* gene, or a functional fragment, subunit or substantially homologous variant thereof, so long as expression of the gene results in a QsbA protein or functional fragment, subunit or variant thereof which inactivates AHL.

[00033] A functional promoter preferably controls expression. Many suitable promoters are known in the art, such that a convenient promoter may easily be selected by a skilled artisan depending on the expression system being used. Such selection of a suitable promoter to achieve the desired level of translational expression is considered routine in the art. For example, it is advantageous to optimize *qsbA* expression by modification of codon usage and coupling to a strong promoter such as the double 35S promoter.

[00034] A suitable marker gene, such as kanamycin resistance, green fluorescent protein or any other convenient marker is advantageously used. Variations of the commonly used and well known methods for transforming plants with a gene, are well within the skill of the ordinary artisan in genetic manipulation of plants. Expression constructs may contain a signal sequence to direct secretion of the expressed QsbA protein, or may lack such a sequence, as desired. The plant transformation vectors containing the *qsbA* gene and a marker gene may be used to transform plant cells using *Agrobacterium*-mediated transformation. *Agrobacterium*-mediated transformation is conveniently used to transform plants with the *qsbA* gene, however any suitable method known in the art may be used, depending on the plant being transformed. For example, certain monocotyledonous plants are more efficiently transformed using other methods such as microprojectile bombardment, vacuum filtration or any other method known in the art to introduce and integrate DNA plasmids or fragments into the plant genome. Those of skill in the art are familiar with means to transform gymnosperms, monocots and dicots. All of these methods known in the art are contemplated for use with this invention.

[00035] After selection for transformants carrying the *qsbA* gene, transgenic plants may be regenerated according to known

methods in the art. Plants selected for a marker gene, for example kanamycin resistance, may be assayed, for example by PCR and DNA gel blot to determine how many copies of the *qsbA* gene are present in the plant tissue. Any suitable method known in the art is contemplated for use with the gene of this invention. QsbA enzyme activity may be detected in transgenic plants transformed with the *qsbA* gene by the bioassay method described in Example 2 or by any convenient method.

[00036] By "functional fragment, subunit or substantially homologous variant thereof," when referring to a *qsbA* nucleotide sequence, it is meant any fragment, subunit, variant or homologous sequence of *qsbA* (nucleotides 1234-3618 of SEQ ID NO: 1) which encodes a protein or peptide sequence capable of inactivating N-acyl homoserine lactones. "Substantially homologous variants" of a nucleotide sequence generally are those the complement of which hybridizes with *qsbA* under stringent or highly stringent conditions, for example temperatures of about 30°C to about 50°C, for example 30°C, 35°C, 37°C, 40°C, 45°C or 50°C, and/or salt concentrations of about 200 mM to about 1000 mM NaCl or the equivalent ionic strength, for example 200 mM, 250 mM, 300 mM, 400 mM, 500 mM, 750 mM or 1000 mM. The stringency conditions are dependent on the length of the nucleic acid and the base composition of the nucleic acid and can be determined by techniques well known in the art. Those of skill in the art are familiar with these conditions and ranges which are useful. Generally, a substantially homologous nucleotide sequence is at least about 75% homologous to SEQ ID NO: 1 or a fragment or subunit thereof, preferably at least about 85% homologous, and most preferably 90%, 95% or 99% homologous or more.

[00037] Those of skill in the art are familiar with the degeneracy of the genetic code, and thus are aware that nucleic acid sequences may be less than 100% homologous and yet encode the same protein or peptide sequence. Such variation in any of the sequences, fragments, subunits or substantially homologous variants also are contemplated as part of this invention.

[00038] Peptide and protein sequences which are encompassed by this invention include any sequences encoded by the *qsbA* gene, or any fragment, subunit or substantially homologous variant thereof. Such sequences therefore include any functional protein or peptide which retains the ability to inactivate AHL, including protein and peptide fragments of the complete QsbA protein, such as, for example, the sequences of amino acids 36-217 and 233-794 encoding by SEQ ID NO: 1 and substantially homologous variants thereof. A substantially homologous variant of the QsbA protein includes sequences which are at least about 50% homologous, preferably at least about 60% homologous, and most preferably 70%, 80% or 90% homologous or more. Therefore, a protein which is a substantially homologous variant of QsbA is about 50% to about 99.9% homologous with QsbA. Both conservative and non-conservative amino acid substitutions are contemplated, as well as sequences containing non-traditional or modified amino acids such as those known in the art.

[00039] The term "fragment" is intended to indicate any portion of the nucleotide of SEQ ID NO: 1 or protein/peptide sequence of SEQ ID NO: 2 which is greater than about 300 nucleotide bases or about 100 amino acids, up to one nucleotide or amino acid less than the entire sequence. The term "subunit" is intended to encompass any functional unit of the QbsA protein, such as, for example, amino acids 36-217 or 233-794 of SEQ ID NO: 2.

[00040] A protein or peptide sequence which is considered to inactivate N-acyl homoserine lactones is one which is capable of inactivating at least 55 pmoles N-acyl homoserine lactone (OOHL) per μ g protein per minute at 30°C.

[00041] It has been previously demonstrated that quenching bacterial quorum sensing by inactivation of N-acyl homoserine lactone with AHL-lactonase stops bacterial infection (9, 10). The gene and protein described here, which is likely an AHL-acylase, represent a new and effective tool for inactivation of AHL signals and thus control bacterial infection. Similarly,

the gene and protein described here targets AHL quorum-sensing signals that regulate expression of pathogenic genes of many bacterial pathogens at a threshold concentration. This tool is applicable to all plant, animal or human diseases where the expression of pathogenic genes of bacterial pathogens is activated by AHL signals, such as, for example, plant pathogens *Erw. carotovora*, *Erw. Chrysanthemi*, *Erw. Stewartii*; human pathogens *P. aeruginosa*, *B. cepacia*; and animal pathogens *X. nematophilus*, *P. fluorescens* (1, 3, 6, 12, 17, 19, 22, 23, 24, 26).

References

1. Allison, et al., "Extracellular products as mediators of the formation and detachment of *Pseudomonas fluorescens* biofilms," *FEMS Microbiol. Lett.* 167:179-184, 1998.
2. Bassler, et al., "Cross-species induction of luminescence in the quorum-sensing bacterium *Vibrio harveyi*," *J. Bacteriol.* 179:4043-4045, 1997.
3. Beck von Badman, and Ferrand, "Capsular polysaccharide biosynthesis and pathogenicity in *Erwinia stewartii* require induction by an *N*-acyl homoserine lactone autoinducer," *J. Bacteriol.* 177:5000-5008, 1995.
4. Cao and Meighen, "Purification and structural identification of an autoinducer for the luminescence system of *Vibrio harveyi*," *J. Biol. Chem.* 264:21670-21676, 1989.
5. Cha et al., "Production of acyl-homoserine lactone quorum-sensing signals by gram-negative plant associated bacteria," *Mol. Plant Microbe Interact.* 11:1119-1129, 1998.
6. Costa and Loper, "EcbI and EcbR: homologs of LuxI and LuxR affecting antibiotic and exoenzyme production by *Erwinia carotovora* subsp. *betavascularum*," *Can. J. Microbiol.* 43:1164-1171, 1997.
7. Daumy et al., "Role of protein subunits in *Proteus retigeri* penicillin G acylase," *J. Bacteriol.* 163:1279-1281, 1985.
8. Davies et al., "The involvement of cell-to-cell signals in the development of a bacterial biofilm," *Science* 280:295-298, 1998.
9. Dong et al., "AiiA, an enzyme that inactivates the acyl homoserine lactone quorum-sensing signal and attenuates the virulence of *Erwinia carotovora*," *Proc. Natl. Acad. Sci. USA* 97:3526-3531, 2000.
10. Dong et al., "Quenching quorum sensing-dependent bacterial infection by an *N*-acyl homoserine lactonase," *Nature* 411:813-817, 2001.
11. Dumenyo et al., "Genetic and physiological evidence for the production of *N*-acyl homoserine lactones by *Pseudomonas syringae* pv. *syringae* and other fluorescent plant pathogenic *Pseudomonas* species," *Eur. J. Plant Pathol.* 104:569-582, 1998.
12. Dunphy et al., "A homoserine lactone autoinducer regulates virulence of an insect-pathogenic bacterium, *Xenorhabdus nematophilus* (Enterobacteriaceae)," *J. Bacteriol.* 179:5288-5291, 1997.

13. Eberhard et al., Structural identification of autoinducer of *Photobacterium fischeri* luciferase," *Biochemistry* 20:2444-2449, 1981.
14. Eberl et al., "Involvement of *N*-acyl-L-homoserine lactone autoinducers in controlling the multicellular behaviour of *Serratia liquefaciens*," *Mol. Microbiol.* 20:127-136, 1996.
15. Fuqua and Winans, "Conserved cis-acting promoter elements are required for density-dependent transcription of *Agrobacterium tumefaciens* conjugal transfer genes," *J. Bacteriol.* 178:435-440, 1996.
16. Inokoshi et al., "Cloning and sequencing of the aculeacin A acylase-encoding gene from *Actinoplanes utahensis* and expression in *Streptomyces lividans*," *Gene* 119:29-35, 1992.
17. Jones et al., "The Lux autoinducer regulates the production of exoenzyme virulence determination in *Erwinia carotovora* and *Pseudomonas aeruginosa*," *EMBO J.* 12:2477-2482, 1993.
18. Leadbetter and Greenberg, "Metabolism of acyl-homoserine lactone quorum sensing signals by *Variovorax paradoxus*," *J. Bacteriol.* 182:6921-6926, 2000.
19. Lewenza et al., "Quorum sensing in *Burkholderia cepacia*: identification of the LuxRI homologs CepRI," *J. Bacteriol.* 181:748-756, 1999.
20. Matsuda and Komatsu, "Molecular cloning and structure of the gene for 7 β -(4-carboxybutanamido)cephalosporadic acid acylase from a *Pseudomonas* strain," *J. Bacteriol.* 163:1222-1228, 1985.
21. Matsuda et al., "Nucleotide sequence of the genes for two distinct cephalosporin acylases from a *Pseudomonas* strain," *J. Bacteriol.* 169:5821-5826, 1987.
22. Nasser et al., "Characterization of the *Erwinia chrysanthemi* *expI-expR* locus directing the synthesis of two *N*-acyl-homoserine lactone signal molecules," *Mol. Microbiol.* 29:1391-1405, 1998.
23. Passador et al., "Expression of *Pseudomonas aeruginosa* virulence genes requires cell-to-cell communication," *Science* 260:1127-1130, 1993.
24. Pearson et al., "Structure of the autoinducer required for expression of *Pseudomonas aeruginosa* virulence genes," *Proc. Natl. Acad. Sci. USA* 91:197-201, 1994.
25. Piper et al., "Conjugation factor of *Agrobacterium tumefaciens* regulates Ti plasmid transfer by autoinduction," *Nature* 362:448-450, 1993.

26. Pirhonen et al., "A small diffusible signal molecule is responsible for the global control of virulence and exoenzyme production in the plant pathogen *Erwinia carotovora*," *EMBO J.* 12:2467-2476, 1993.
27. Schumacher et al., "Penicillin acylase from *E. coli*: unique gene-protein relation," *Nucleic Acids Res.* 14:5713-5727, 1986.
28. Staskawicz et al., "Molecular characterization of cloned avirulence genes from race 0 and race 1 of *Pseudomonas syringae* pv. *glycinea*," *J. Bacteriol.* 169:5789-5794, 1987.
29. Takeshima et al., "A deacylation enzyme for aculeacin A, a neutral lipopeptide antibiotic, from *Actinoplanes utahensis*: purification and characterization," *J. Biochem.* 105:606-610, 1989.
30. Verhaert et al., "Molecular cloning and analysis of the gene encoding the thermostable penicillin G acylase from *Alcaligenes faecalis*," *Appl. Env. Microbiol.* 63:3412-3418, 1997.
31. Zhang et al., "Agrobacterium conjugation and gene regulation by *N*-acyl-L-homoserine lactones," *Nature* 362:446-447, 1993.

[00042] The following examples are provided to illustrate the invention described herein and should not be construed to limit the appended claims.

EXAMPLES

Example 1. Bacterial Isolation.

[00043] A bacterial biofilm sample was collected from a water treatment system and screened to isolate AHL inactivation bacterial strains. The bacterial mixture was suspended in sterilized water with shaking for 1 hour before spreading onto YEB medium (yeast extract, 5 g/l; casein hydrolysate, 10 g/l; NaCl, 5 g/l; sucrose, 5 g/l; MgSO₄·7H₂O, 0.5 g/l and agar, 15 g/l) plates. Individual colonies were restreaked on new plates to ensure purity of the isolates. Bacterial isolates were cultured in LB medium (tryptone, 10 g/L; yeast extract, 5 g/L, and NaCl, 10 g/L; pH7.0) in 1.5-ml Eppendorf™ tubes or 96-well plates at 28°C, with shaking, overnight, and assayed for AHL inactivation activity.

Example 2. AHL Inactivation Bioassay.

[00044] The bacterial culture to be assayed was mixed with an equal volume of fresh medium containing 20 μ M N- β -oxooctanoyl-L-homoserine lactone (OOHL), or another AHL, when specified, to form a reaction mixture. The reaction mixture was incubated at 28°C for 4 to 5 hours, followed by 30 minute sterilization under UV light. Plates containing 20 ml MM agar medium (K_2HPO_4 , 10.5 g/L; KH_2PO_4 , 4.5 g/L; $MgSO_4 \cdot 7H_2O$, 0.2 g/L; $FeSO_4$, 4.5 mg/L; $CaCl_2$, 10 mg/L; $MnCl_2$, 2 mg/L; $(NH_4)_2SO_4$, 2.0 g/L; mannitol, 2.0 g/L; pH 7.0) supplemented with 5-bromo-4-chloro-3-indolyl β -D-galactopyranoside (X-Gal, 40 μ g/ml) were prepared. The solidified medium was cut, still inside the plate, into separated slices (approximately 1 cm in width). See Figure 1. Five microliters of sterilized reaction mixture was loaded at the top of an MM agar strip, and then AHL indicator cells (*Agrobacterium tumefaciens* strain NT1 (*traR*; *tra::lacZ749*) (25) 0.7 μ l cell suspension with an optical density at 600 nm of 0.4) were spotted at progressively further distances from the loaded samples. Plates were incubated at 28°C for 24 hours. A positive result for AHL inactivation is shown by the absence of blue colonies on the slice. A negative result for AHL inactivation is shown by the presence of blue colonies on the slice. For assay of protein for enzyme activity, total soluble bacterial protein was incubated with 20 μ M of OOHL (or other AHL) at 37°C for 1 hour as the reaction mixture.

Example 3. Identification and Cloning the *qsba* Gene.

[00045] Two bacterial isolates from the biofilm sample with distinct phenotypes, XJ12B and XJ12A, were found to possess the ability to inactivate AHL, with XJ12B showing stronger enzyme activity. The XJ12B isolate was cultured, centrifuged and sonicated. The strongest enzymatic activity was associated with the cell debris fraction rather than the soluble protein and supernatant fractions. These results indicated that the AHL inactivation activity is membrane associated. Sequencing of 16S rRNA was performed to identify the XJ12A and XJ12B isolates.

The 16S rRNA sequences of these isolates showed 97% and 96% identity, respectively, with that of *Ralstonia eutropha*.

[00046] To identify the gene encoding for AHL inactivation, a cosmid library of 1600 clones was constructed in *E. coli* with the genomic DNA of *Ralstonia sp.* strain XJ12B. Genomic DNA from the isolated *Ralstonia sp.* strain XJ12B was partially digested with Sau3A. The resulting DNA fragments were ligated to the dephosphorylated BamH1 site of cosmid vector pLAFR3 (28). The ligated DNA was packed with Gigapack IIIIXL Packaging Extract (Stratagene) and transfected into *E. coli* DH5alpha. These *E. coli* transfectants were screened for AHL inactivation activity according to the methods described in Example 2 using OOHL as the substrate. Only a single clone (p13H10) was identified as showing AHL inactivation activity (see Figure 1A, slice 1). To subclone the gene encoding the detected activity, cosmid DNA from the positive clone p13H10 was partially digested with Sau3A and fused into BamH1 digested cloning vector pGEM-3Zf (+). The plasmids were ligated and transformed into *E. coli*, and the *E. coli* were assayed for the ability to inactivate AHL as described in Example 2. Clone p2B10, which contains a 4 kb insert, had AHL inactivation activity (see Figure 1A, slice 2). The TGS™ Template Generation System F-700 (Finnzymes OY) was used to mutate p2B10 plasmid DNA by randomly inserting the artificial Mu transposon, following the manufacturer's instructions. Plasmid clone p2B10, which contains the 4 kb insert containing the *gsbA* gene, was used as a template. Fifteen mutant clones were produced, and none was able to inactivate AHL. Bacterial cultures of *E. coli* DH5α containing pMUG3 and pMUC6 are shown as examples in Figure 1A, slices 3 and 4, respectively. Plasmids were subsequently purified for sequencing using primers supplied in the kit.

Example 4. Sequencing and Sequence analysis of the *gsbA* Gene.

[00047] Sequencing was performed according to known methods using ABI Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer Applied Biosystems). The 4 kb

fragment from clone p2B10 was completely sequenced and is shown in Table I. The sequence contains an open reading frame of 2385 nucleotides with an ATG start codon and a TGA stop codon (SEQ ID NO: 1, nucleotides 1259-3643). Based on the MU transposon mutagenesis data described in Example 3, this open reading frame is the coding region of the AHL inactivation gene, designated as *qsbA*. A putative ribosome binding site (AGGAGA) is located 6 base pairs upstream of the first ATG start codon (underlined in Table I).

[00048] The deduced peptide sequence shows the typical polypeptide primary structure of aculeacin A acylases (AACs) and penicillin G acylases, with signal peptide- α subunit-spacer- β subunit organization (16, 30). There are four additional potential start codons located 3, 36, 189 and 384 downstream from the first ATG. The longest open reading frame encodes 794 amino acids, with a predicted molecular weight of 85373 Daltons. The deduced peptide has 78 strongly basic and strong acid amino acid residues and a predicted isoelectric point of 7.48. The first 20 amino acid residues of the assumed open reading frame appear to be a signal peptide.

[00049] The peptide sequence of *qsbA* deduced from the open reading frame shares 40-52% identity with AACs from *Deinococcus radiodurans* strain R1, *Actinoplanes utahensis* and a putative acylase from *Pseudomonas aeruginosa*. The AACs' catalyze deacylation of their substrates. These AAC genes are translated as single precursor polypeptide and then processed to the active form of two subunits. By alignment with the peptide sequences from *D. radiodurans* strain R1, *A. utahensis* and *P. aeruginosa*, Table II, the presumed α and β subunits are located at amino acid positions 36-217 and 233-794, respectively, with a 15 amino acid spacer between them. *QsbA* shares less than 28% homology with penicillin G acylase (20) and cephalosporin acylase (21). See Table II. The amino acid sequence alignment in Table II was analyzed by the Clustal W program available from the European Bioinformatics Institute website (<http://www.ebi.ac.uk>).

Example 5. Expression of the *QsbA* Gene.

[00050] The coding region of the *qsbA* gene was amplified by PCR using a forward primer 5'-

CGTGGATCCATGATGCAGGATTCGCCGCTGCGC-3' (SEQ ID NO: 6) and a reverse primer 5'- CGCGAATTCACCGGCAGCCCTCATGCGACAAC-3' (SEQ ID NO: 7) containing BamH1 and EcoR1 restriction sites, respectively. The amplified PCR products were digested using the above restriction enzymes and fused in-frame to the coding sequence of the glutathione S-transferase (GST) gene under the control of the isopropyl β -D-thiogalactopyranoside (IPTG) inducible lac promotor in vector pGEX-2T (Amersham Pharmacia) to generate construct pGST-QsbA. pGST-QsbA was transformed into *E. coli* and expressed.

[00051] Total soluble protein was extracted from the recombinant *E. coli* cells harboring the GST-QsbA-encoding fusion construct according to methods known in the art, based on the methods described in Dong et al. (9), and assayed for AHL inactivation. The total soluble protein from *E. coli* containing GST vector only was used as a control. For the bioassay, 50 μ l of the soluble protein preparation (20 μ g/ μ l) was added to the same volume of 40 μ M AHL, e.g., OOHL. After a 1 hour incubation at 37°C, the reaction mixture was assayed as described in Example 2. Representative data, shown in Figure 1B, slice 1, indicate that the soluble GST-QsbA fusion protein effectively eliminated OOHL activity.

Example 6. Characterization of the Substrate Spectrum of GST-QsbA Fusion Protein Expressed in *E. coli*.

[00052] To determinate the substrate spectrum of QsbA, total soluble protein extracted from the recombinant *E. coli* (pGST-QsbA) was assayed for inactivation of AHLs with acyl chains of differing lengths according to the methods of Example 2. The following AHLs were synthesized according to known methods as described by Zhang et al. (31): (1) N-octanoyl-L-homoserine lactone (C8HSL, OOHL); (2) N-decanoyl-L-homoserine lactone (C10HSL, DHL); (3) N- β -oxohexanoyl-L-homoserine lactone (3-oxo-

C6HSL, OHHL); (4) N- β -oxohexanoyl-L-homoserine lactone (3-oxo-C12HSL, OdDHL); (5) N- β -oxohexanoyl-L-homoserine lactone (3-oxo-C8HSL, OOHL). The butyl and hexyl esters of N- β -oxohexanoyl-L-homoserine were prepared by esterification of N- β -oxohexanoyl-L-homoserine lactone with 1-butanol and 1-hexanol respectively, in the presence of small amount of Dowex 50H+ resin (Aldrich). The reaction was conducted at 60°C for 2 hours and the products were purified by silica column chromatography.

[00053] QsbA completely inactivated OOHL, N- β -oxodecanoyl-L-homoserine (ODHL) and N- β -oxododecanoyl-L-homoserine (OdDHL), which have acyl chains of 8, 10 and 12 carbons, respectively, at the concentrations tested (data not shown). QsbA also strongly inactivated N- β -octanoyl-L-homoserine(OHL) and N- β -decanoyl-L-homoserine(DHL), which have acyl chains of 8 and 10 carbons, respectively (data not shown). However, under the same reaction conditions, QsbA had less inactivating activity for N- β -oxohexanoyl-L-homoserine (OHHL), which has an acyl chain of 6 carbons (data not shown). The total soluble protein extract from control *E.coli* (pGST) did not show any activity against AHLs (data not shown).

[00054] QsbA also completely inactivated the butyl and hexyl esters of N- β -octanoyl-L-homoserine (data not shown). These two esters of N- β -octanoyl-L-homoserine showed comparable induction activity with OOHL when assayed with the AHL reporter strain *A. tumefaciens* NT1 (*traR*; *tra::lacZ749*) (data not shown). AHL-lactonase (encoded by *aiiA*) did not inactivate these substrates. These substrate specificity data are consistent with identification of QsbA as an AHL-acylase.

Example 7. Purification of AHL-acylase encoded by the *qsbA* gene

[00055] The GST-[AHL-acylase] fusion protein was purified using a glutathione Sepharose 4B affinity column following the manufacturer's instructions (Pharmacia). AHL-acylase was cleaved by digestion with thrombin (Sigma). Protein concentration was determined by measuring OD₂₈₀.

[00056] The purified AHL-acylase was incubated with OOHL for 20 minutes and the relative enzyme activity was measured by determining the residual OOHL in the reaction mixture, which contained 8 μ M OOHL and about 0.6 μ g AHL-acylase in a total reaction volume of 50 ml 1x PBS buffer. The reactions were stopped by addition of 1% SDS before loading on the assay plate. Determination of the OOHL activity was carried out in quadruplicate. AHL-acylase degraded OOHL in a range of temperatures from 22-42°C at pH 7.0. See Figure 2. The optimal temperature for enzyme activity was found to be approximately 28°C. Reaction temperature higher than 42°C decreased enzyme activity sharply. The optimal pH for enzyme activity also was determined. The AHL-acylase has a relatively narrow optimal pH range from pH 6.5 to 7.5. See Figure 2. The time course of OOHL inactivation by the purified AHL-acylase was determined at 30°C. See Figure 3. After 10 minutes, more than 82% OOHL had been degraded; the reaction rate was estimated to be about 55 pmols per μ g AHL-acylase per minute.

CLAIMS:

1. A composition of matter which comprises a nucleic acid according to SEQ ID NO: 1.
2. A composition of matter which comprises a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.
3. A nucleic acid according to claim 2 which comprises nucleotides 1234-3618 of SEQ ID NO: 1.
4. A composition of matter which comprises a peptidic sequence selected from the group consisting of a peptidic sequence according to SEQ ID NO: 2, a fragment thereof and a substantially homologous variant thereof.
5. A composition of matter which comprises a peptidic sequence encoded by a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.
6. A composition of matter which comprises a peptidic sequence selected from the group consisting of SEQ ID NO: 2, a fragment thereof, a subunit thereof and a substantially homologous variant thereof.
7. A composition of matter according to claim 6 which comprises a peptidic sequence according to SEQ ID NO: 2.
8. A composition of matter according to claim 6 which comprises a peptidic sequence comprising amino acids 36-217 of SEQ ID NO: 2.

9. A composition of matter according to claim 6 which comprises a peptidic sequence comprising amino acids 233-794 of SEQ ID NO: 2.

10. A composition of matter according to claim 6 which inactivates AHL.

11. A method of modulating AHL signaling activity which comprises contacting said AHL with a composition of matter according to any one of claims 5-10.

12. A transgenic plant harboring a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.

13. A transgenic non-human animal harboring a nucleic acid selected from the group consisting of nucleotides 1234-3618 of SEQ ID NO: 1, a fragment thereof and a substantially homologous variant thereof.

14. A method of controlling a bacterial disease in a mammal in need thereof which comprises administering to said mammal a composition of matter according to any one of claims 5-10, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

15. A method of claim 14 wherein said mammal is a human.

16. A method of controlling a bacterial disease in a plant in need thereof which comprises administering to said plant a composition of matter according to any one of claims 5-10, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

17. A method of controlling a bacterial disease in a mammal in need thereof which comprises administering to said mammal a

composition of matter of claim 2 and its peptide product, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

18. A method of claim 17 wherein said mammal is a human.

19. A method of controlling a bacterial disease in a plant in need thereof which comprises administering to said plant a composition of matter of claim 2, wherein the expression of pathogenic genes of said bacteria are regulated by AHL signals.

20. A method of controlling a bacterial disease in a plant using any bacterial species containing the composition of matter of claim 2.

RALSTONIA AHL-ACYLASE GENE

ABSTRACT OF THE DISCLOSURE

[00058] This invention provides a gene, *qsba*, which encodes a protein useful for inactivating certain bacterial quorum-sensing signal molecules (N-acyl homoserine lactones) which participate in bacterial virulence and biofilm differentiation pathways. This gene was isolated from *Ralstonia sp.*, strain XJ12B. The invention also provides the QsbA protein, which possesses N-acyl homoserine lactone inactivating activity.

2577-154.PCT

Fig. 1

1/2




FIG. 1A




FIG. 1B

2/2




FIG. 2A




FIG. 2B




FIG. 3

SEQUENCE LISTING

<110> Zhang, Lian Hui

Lin, Yi Han

Xu, Jin Ling

<120> RALSTONIA AHL-ACYLASE GENE

<130> 2577-154 PCT

<160> 7

<170> PatentIn version 3.0

<210> 1

<211> 3743

<212> DNA

<213> Ralstonia sp.

<220>

<221> N_region

<222> (16)..(16)

<223> unknown

<400> 1

gtttgggaaa gtgggnagcg cgctgtgcag cgccccgccc ctcagccgcg cagctcggcg	60
cgcaccgaat gcgcgcgccc gtgggcgccc ggcggctggc cgggtgtggcg ccggatcagg	120
cgccggaagg cggacatgtc gtgataaccg cactgttcgg cgattgccgt caggctcagc	180
gtgctgactt ccagcaggtg gcaggcgcg cccacgcgca gccggtgcag caattgcagc	240

ggcgaggtgc ccaggggtctt ggtgaaatgc cgcagcagcg tgcgctcgct ggtcgaggcg 300
 gcggcgggcca gcttggccag gtcgaacggc tcgtgcaggt gctgctgcag gtagcgccgc 360
 gcccgagta ccacgctggt gcggatggcg ggcttgcctgc gcagccagat ggcggtggac 420
 tcaccgcgcg acgggtggtc gagcacggcc tggccgaggg tgcgtgccag ccgggtgtcg 480
 gccaggcggc cgaccaggcg ctgcgtgagc gccacgccgt gctccatcgc gcgcgccgtc 540
 agcacgttgc cgctgctgac gatggcctgc tccgccacca ccttcagctg cgggtagttg 600
 ccgtgcagcc agccggcgat cagccacgtc accgtcaagc gccggccggc gggcagcgcg 660
 ccggccagca gcgccacgcc ggtgaaggac gaggccacca agcctgccgg cgtccaggta 720
 gcgccggatg gtggcgcggtt cccactccag cagggccagg cgctgctcca gcgtgctgat 780
 gtggctgaaa tgcaggggcg ggacgaccag cgcgtcgccc agcgcggcgt cgcccgccgg 840
 cagcggttg cagcggcagg ccaggggtctc ggcggcggcc tgccagcggg ccgggtcgcg 900
 cgcgaccagc cgccaccga acaccgggct ggcggcacgc gcacgcttgc cggcatgcat 960
 ggaggcgagc gcattggcca cgccgaggggt gtcggcgacg gtcgccagcg tggagaggcc 1020
 ggcgtcgga aaggtcagca ggtcgatgtc ggcacccga aagtataggg gaggcggcg 1080
 gaggcctcct gcgtggcggg attgacccca actctggcg gaatacctct ttctccggg 1140
 cgggccccag tcgacgatac ggcggtggct gcgcctgcgc gccgccgcaa gactagagcg 1200
 acacaagaca agaccgacaa caggagacaa cgcattgatc agggattcgc gctgcgcggc 1260
 acgtcgcca tggcgcgcgt cgcggcgctg gccggctgcg ccagttccac cgatggccgc 1320
 tgggggtcgc tcagcgacac cggcctgtcc gccgagatcc gccgcaccgg ctccggcatt 1380
 ccgcacatcc gcgccaacga ctacgccagc ctcggtatg gcatggccta tgcctacgcg 1440
 caggacaacc tgtgcctgct ggccgaccag gtggtcaccg tcaacggcga gcgctcgaag 1500
 accttcgggc ccgagggcac cgtgacggtc tcgttcaagc cgatcccca cctgcagtcg 1560
 gacgccttct tcaagggcat cttcgacgag gacggcctgc gcgccgtta tgcgcagatg 1620
 tcgcccgagg cgcgcgagct gctgcgcggc tacatcgccg gcttcaaccg ctatctcaag 1680
 gacacgccgc ccgccaaactt cccggccgcc tgccgcaatg ccgcctgggt gcgtccgctc 1740
 acgttgggcg acatgatgcg catgggcgaa gagaaggcga tccaggccag cgccggcgcc 1800
 atgctggcg gcacgtcgc cgcgcagccg ccgggcccga cgcgggtggc cgagcgcgag 1860
 attccgccgc aggcgctcga caccgtggcg ctggaccgcg aactgcagct gcgcgacatg 1920
 ccgatcggct ccaacggctg ggccttcggc gctgacgcca ccgccaacg gcgcggcggtg 1980

ctgctcggca	atccgcactt	cccgtggacg	accaccaacc	gcttctacca	ggtccacctg	2040
acggtgcccg	gcaagctcga	cgtgatgggc	gcctcgatcg	cgcccttccc	ggtggtgagc	2100
atcggcttca	acaaggacgt	ggcgtggacg	cacaccgtct	ccaccggccg	ccgcttcacc	2160
ttgttcgaac	tgaagctggc	cgaaggcgac	ccgaccacct	acctggtcga	cggcacgccc	2220
cacaagatga	ccaccgcac	ggtcgccttc	gacgtcaagc	tgccggacgg	ccgcctcgag	2280
cgccgcacgc	acaccttcta	cgacaccatc	tacggcccgg	tgtgtcgat	gccgagcggc	2340
ggcatgccgt	ggaccacgca	gaaggcctac	gccctgcgcg	acgccaaccg	caacaacacg	2400
cgctcggtcg	acagctggct	gcatatcggg	caggcccggg	acgtggccgg	catccgccag	2460
gccatcggca	acctgggcat	tccctgggtc	aacaccatcg	ccaccgaccg	caacggccgc	2520
gcgctgttcg	ccgacgtgtc	gaccacgccc	gacgtgccgg	ccgcgagct	ccagcgctgt	2580
gcccgtcgc	cgctggccgg	caaactcttc	aaggacgcgg	gcctggtgct	gctcgacggc	2640
tcgcgcggca	cctgcaactg	gcaggtcgat	ccggcttcgc	cggtaccggg	gctggtggcg	2700
cccgcgcgca	tgccggtgct	cgagcgcgac	gactacgtcg	ccaacagcaa	tgacagctcc	2760
tggtgacca	accccgcgca	aaagctgacc	ggcttctcgc	cggtgatggg	ctcggtcgac	2820
gtaccgcagc	ggctgcgcac	gcgcacggc	ctgatcgaga	tcggccgccc	cctggccggc	2880
accgacggac	tgcccggcaa	ccgcacgat	ctgccgaacc	tgaggcgat	gatcttcagc	2940
aatgccaacc	tggcgggaca	actggtgctg	ggcgacctgc	tcgcggcatg	caaggccacg	3000
ccggccccgg	atgccgacgt	gcgcgacggc	tgccgcgcc	tcggccagtg	gaaccgcacc	3060
agcaacgccg	acgcccgcgc	cgcgacacctg	ttccgcgagt	tctggatgcg	cgccaaggac	3120
atcgcgcagg	tgacgcgcgt	cgagttcgac	ccggccgacc	cggtccacac	gccgcgcggc	3180
ctgcgcgatga	acgacgcgac	ggtacgcacg	gcggtgttca	aggcgctgaa	ggaagccgtg	3240
ggcgcggtgc	gcaaggcggg	cttcgcgctg	gatgcgccgc	tgggcacggt	acaggccgcg	3300
cacgcaccgg	acggctccat	cgccctgcac	ggcggcgagg	aatacgaagg	cgtgctcaac	3360
aagctgcaaa	ccctgccgat	cgggccgaag	gggctgccgg	tgtatttcgg	caccagctac	3420
atccagaccg	tgaccttcga	cgaccagggc	ccggtcgccg	acgccatcct	cacctacggc	3480
gaatcgaccg	accacgcctc	gccgcacgcg	ttcgaccaga	tgctgctgta	ctcgggcaag	3540
cactggaacc	ggctgccgtt	ctccgaagcg	gccatcgccg	ccgatccggc	gctgaagggtg	3600
atgcggttgt	cgcagtgagg	gctgccggtg	cctggaaaaa	cgccccgctt	gtgcggggcg	3660
tttttttgcc	agtgtgaatg	gctcaatcgt	gttggaacc	gcatccggac	atgactgtat	3720

tgtgactctg cctgtgtccg tgt

3743

<210> 2

<211> 794

<212> PRT

<213> Ralstonia sp.

<400> 2

Met	Met	Gln	Gly	Phe	Ala	Leu	Arg	Gly	Thr	Leu	Ala	Met	Ala	Ala	Leu
1				5					10					15	
Ala	Ala	Leu	Ala	Gly	Cys	Ala	Ser	Ser	Thr	Asp	Gly	Arg	Trp	Gly	Ser
			20					25					30		
Leu	Ser	Asp	Thr	Gly	Leu	Ser	Ala	Glu	Ile	Arg	Arg	Thr	Gly	Phe	Gly
		35					40					45			
Ile	Pro	His	Ile	Arg	Ala	Asn	Asp	Tyr	Ala	Ser	Leu	Gly	Tyr	Gly	Met
	50					55					60				
Ala	Tyr	Ala	Tyr	Ala	Gln	Asp	Asn	Leu	Cys	Leu	Leu	Ala	Asp	Gln	Val
65					70				75					80	
Val	Thr	Val	Asn	Gly	Glu	Arg	Ser	Lys	Thr	Phe	Gly	Pro	Glu	Gly	Thr
				85					90					95	
Val	Thr	Val	Ser	Phe	Lys	Pro	Ile	Pro	Asn	Leu	Gln	Ser	Asp	Ala	Phe
			100					105					110		
Phe	Lys	Gly	Ile	Phe	Asp	Glu	Asp	Gly	Leu	Arg	Ala	Gly	Tyr	Ala	Gln
		115					120					125			
Met	Ser	Pro	Glu	Ala	Arg	Glu	Leu	Leu	Arg	Gly	Tyr	Ile	Ala	Gly	Phe
	130					135					140				
Asn	Arg	Tyr	Leu	Lys	Asp	Thr	Pro	Pro	Ala	Asn	Phe	Pro	Ala	Ala	Cys
145					150					155					160
Arg	Asn	Ala	Ala	Trp	Val	Arg	Pro	Leu	Thr	Leu	Gly	Asp	Met	Met	Arg
				165					170					175	
Met	Gly	Glu	Glu	Lys	Ala	Ile	Gln	Ala	Ser	Ala	Gly	Ala	Met	Leu	Ala
			180					185					190		
Gly	Ile	Val	Ala	Ala	Gln	Pro	Pro	Gly	Arg	Thr	Pro	Val	Ala	Glu	Arg
		195					200					205			
Glu	Ile	Pro	Pro	Gln	Ala	Val	Asp	Thr	Val	Ala	Leu	Asp	Arg	Glu	Leu
	210					215					220				

Gln	Leu	Arg	Asp	Met	Pro	Ile	Gly	Ser	Asn	Gly	Trp	Ala	Phe	Gly	Ala	225	230	235	240
Asp	Ala	Thr	Ala	Asn	Arg	Arg	Gly	Val	Leu	Leu	Gly	Asn	Pro	His	Phe	245	250	255	
Pro	Trp	Thr	Thr	Thr	Asn	Arg	Phe	Tyr	Gln	Val	His	Leu	Thr	Val	Pro	260	265	270	
Gly	Lys	Leu	Asp	Val	Met	Gly	Ala	Ser	Ile	Ala	Ala	Phe	Pro	Val	Val	275	280	285	
Ser	Ile	Gly	Phe	Asn	Lys	Asp	Val	Ala	Trp	Thr	His	Thr	Val	Ser	Thr	290	295	300	
Gly	Arg	Arg	Phe	Thr	Leu	Phe	Glu	Leu	Lys	Leu	Ala	Glu	Gly	Asp	Pro	305	310	315	320
Thr	Thr	Tyr	Leu	Val	Asp	Gly	Thr	Pro	His	Lys	Met	Thr	Thr	Arg	Thr	325	330	335	
Val	Ala	Phe	Asp	Val	Lys	Leu	Pro	Asp	Gly	Arg	Leu	Glu	Arg	Arg	Thr	340	345	350	
His	Thr	Phe	Tyr	Asp	Thr	Ile	Tyr	Gly	Pro	Val	Leu	Ser	Met	Pro	Ser	355	360	365	
Gly	Gly	Met	Pro	Trp	Thr	Thr	Gln	Lys	Ala	Tyr	Ala	Leu	Arg	Asp	Ala	370	375	380	
Asn	Arg	Asn	Asn	Thr	Arg	Ser	Val	Asp	Ser	Trp	Leu	His	Ile	Gly	Gln	385	390	395	400
Ala	Arg	Asp	Val	Ala	Gly	Ile	Arg	Gln	Ala	Ile	Gly	Asn	Leu	Gly	Ile	405	410	415	
Pro	Trp	Val	Asn	Thr	Ile	Ala	Thr	Asp	Arg	Asn	Gly	Arg	Ala	Leu	Phe	420	425	430	
Ala	Asp	Val	Ser	Thr	Thr	Pro	Asp	Val	Pro	Ala	Ala	Glu	Leu	Gln	Arg	435	440	445	
Cys	Ala	Pro	Ser	Pro	Leu	Ala	Gly	Lys	Leu	Phe	Lys	Asp	Ala	Gly	Leu	450	455	460	
Val	Leu	Leu	Asp	Gly	Ser	Arg	Gly	Thr	Cys	Asn	Trp	Gln	Val	Asp	Pro	465	470	475	480
Ala	Ser	Pro	Val	Pro	Gly	Leu	Val	Ala	Pro	Ala	Arg	Met	Pro	Val	Leu	485	490	495	
Glu	Arg	Asp	Asp	Tyr	Val	Ala	Asn	Ser	Asn	Asp	Ser	Ser	Trp	Leu	Thr	500	505	510	
Asn	Pro	Ala	Gln	Lys	Leu	Thr	Gly	Phe	Ser	Pro	Val	Met	Gly	Ser	Val	515	520	525	

Asp	Val	Pro	Gln	Arg	Leu	Arg	Thr	Arg	Ile	Gly	Leu	Ile	Glu	Ile	Gly
530						535					540				
Arg	Arg	Leu	Ala	Gly	Thr	Asp	Gly	Leu	Pro	Gly	Asn	Arg	Ile	Asp	Leu
545					550					555					560
Pro	Asn	Leu	Gln	Ala	Met	Ile	Phe	Ser	Asn	Ala	Asn	Leu	Ala	Gly	Gln
				565					570					575	
Leu	Val	Leu	Gly	Asp	Leu	Leu	Ala	Ala	Cys	Lys	Ala	Thr	Pro	Ala	Pro
			580					585					590		
Asp	Ala	Asp	Val	Arg	Asp	Gly	Cys	Ala	Ala	Leu	Gly	Gln	Trp	Asn	Arg
		595					600					605			
Thr	Ser	Asn	Ala	Asp	Ala	Arg	Ala	Ala	His	Leu	Phe	Arg	Glu	Phe	Trp
	610					615					620				
Met	Arg	Ala	Lys	Asp	Ile	Ala	Gln	Val	His	Ala	Val	Glu	Phe	Asp	Pro
625					630					635					640
Ala	Asp	Pro	Val	His	Thr	Pro	Arg	Gly	Leu	Arg	Met	Asn	Asp	Ala	Thr
				645					650					655	
Val	Arg	Thr	Ala	Val	Phe	Lys	Ala	Leu	Lys	Glu	Ala	Val	Gly	Ala	Val
			660					665					670		
Arg	Lys	Ala	Gly	Phe	Ala	Leu	Asp	Ala	Pro	Leu	Gly	Thr	Val	Gln	Ala
		675					680					685			
Ala	His	Ala	Pro	Asp	Gly	Ser	Ile	Ala	Leu	His	Gly	Gly	Glu	Glu	Tyr
	690					695					700				
Glu	Gly	Val	Leu	Asn	Lys	Leu	Gln	Thr	Leu	Pro	Ile	Gly	Pro	Lys	Gly
705					710					715					720
Leu	Pro	Val	Tyr	Phe	Gly	Thr	Ser	Tyr	Ile	Gln	Thr	Val	Thr	Phe	Asp
				725					730					735	
Asp	Gln	Gly	Pro	Val	Ala	Asp	Ala	Ile	Leu	Thr	Tyr	Gly	Glu	Ser	Thr
			740					745					750		
Asp	His	Ala	Ser	Pro	His	Ala	Phe	Asp	Gln	Met	Arg	Ala	Tyr	Ser	Gly
		755					760					765			
Lys	His	Trp	Asn	Arg	Leu	Pro	Phe	Ser	Glu	Ala	Ala	Ile	Ala	Ala	Asp
	770					775					780				
Pro	Ala	Leu	Lys	Val	Met	Arg	Leu	Ser	Gln						
785					790										

<210> 3

<211> 785

<212> PRT

<213> D. radiodurans

<400> 3

```

Met Ser Arg Ser Pro Phe Ser Ser Val Ser Leu Pro Ala Arg Leu Leu
1          5          10          15
Leu Gly Ser Leu Leu Leu Gly Pro Leu Met Leu Gly Gly Ala Ala Ser
20          25          30
Ala Gln Thr Tyr Gln Val Gln Ile Gln Arg Thr Ala His Gly Ile Pro
35          40          45
His Ile Gln Ala Ser Asp Leu Gly Gly Ile Gly Tyr Gly Val Gly Tyr
50          55          60
Ser Tyr Ala Gln Asp Asn Leu Cys Leu Leu Ala Asp Gln Val Met Thr
65          70          75          80
Val Arg Gly Glu Arg Ser Lys Phe Leu Gly Ala Glu Gly Lys Thr Val
85          90          95
Val Gly Phe Gln Pro Val Asn Asn Leu Asp Ser Asp Val Phe Phe Lys
100         105         110
Thr Val Ile Glu Pro Gly Arg Leu Gln Ala Gly Tyr Arg Asp Gln Pro
115         120         125
Gln Ile Leu Ala Leu Met Arg Gly Tyr Val Ala Gly Val Asn Arg Tyr
130         135         140
Leu Arg Asp Thr Pro Pro Glu Gln Trp Pro Ser Ala Cys Arg Asn Ala
145         150         155         160
Asp Trp Val Arg Pro Leu Thr Glu Leu Asp Val Met Arg Leu Gly Glu
165         170         175
Glu Lys Ala Ile Gln Ala Ser Ala Gly Ala Met Val Ser Ala Ile Thr
180         185         190
Ser Ala Arg Pro Pro Gln Ala Gly Ala Ser Thr Ala Ala Pro Arg Pro
195         200         205
Asp Leu Ala Ala Phe Asn Arg Gln Tyr Arg Phe Asn Asp Leu Pro Ile
210         215         220
Gly Ser Asn Gly Trp Ala Phe Gly Ser Glu Ala Thr Thr Asn Gly Arg
225         230         235         240

```

Gly	Leu	Leu	Leu	Gly	Asn	Pro	His	Phe	Pro	Trp	Glu	Thr	Ser	Asn	Arg	
				245					250					255		
Phe	Tyr	Gln	Leu	His	Leu	Thr	Leu	Pro	Gly	Gln	Phe	Asp	Val	Met	Gly	
			260					265					270			
Ala	Ser	Leu	Gly	Gly	Met	Pro	Val	Val	Asn	Ile	Gly	Phe	Asn	Gln	Asp	
		275					280					285				
Val	Ala	Trp	Thr	His	Thr	Val	Ser	Thr	Asp	Lys	Arg	Phe	Thr	Leu	Ala	
	290					295					300					
Ala	Leu	Thr	Leu	Val	Pro	Gly	Asp	Pro	Leu	Ser	Tyr	Val	Lys	Asp	Gly	
305					310					315					320	
Gln	Gln	Arg	Arg	Leu	Gln	Arg	Arg	Thr	Ala	Val	Ile	Glu	Val	Lys	Thr	
				325					330					335		
Ala	Asn	Gly	Pro	Arg	Leu	His	Thr	Arg	Thr	Val	Tyr	Phe	Thr	Pro	Glu	
			340					345					350			
Gly	Pro	Leu	Val	Asn	Leu	Pro	Ala	Ala	Gly	Leu	Thr	Trp	Thr	Pro	Gln	
		355					360					365				
Tyr	Ala	Phe	Ala	Leu	Arg	Asp	Ala	Asn	Arg	Asn	Asn	Thr	Arg	Met	Leu	
	370					375					380					
Ala	Thr	Trp	Leu	Gly	Phe	Ala	Gly	Ala	Lys	Ser	Val	Arg	Asp	Ile	Arg	
385					390					395					400	
Ala	Ser	Leu	Asn	Val	Gln	Gly	Ile	Pro	Trp	Val	Asn	Thr	Ile	Ala	Ala	
			405						410					415		
Asp	Arg	Ala	Gly	Ser	Ala	Leu	Tyr	Ala	Asp	Ile	Ser	Ser	Ser	Pro	Asn	
			420					425					430			
Val	Ser	Ala	Ala	Gln	Gln	Gln	Ala	Cys	Thr	Pro	Pro	Pro	Leu	Ala	Pro	
		435					440					445				
Leu	Phe	Pro	Ala	Ala	Gly	Leu	Ala	Val	Leu	Asp	Gly	Ser	His	Ser	Ala	
	450					455					460					
Cys	Asp	Trp	Lys	Thr	Asp	Pro	Ala	Ser	Arg	Val	Pro	Gly	Leu	Arg	Ala	
465					470					475					480	
Pro	Asp	Lys	Met	Pro	Val	Leu	Ile	Arg	Gln	Asp	Phe	Val	Ala	Asn	Ser	
			485						490					495		
Asn	Asn	Ser	Ala	Trp	Leu	Ala	Asn	Pro	Ala	Ala	Pro	Gln	Thr	Gly	Leu	
			500					505					510			
Asp	Pro	Leu	Val	Gly	Glu	Val	Asn	Ala	Pro	Gln	Ser	Pro	Arg	Thr	Arg	
		515					520					525				
Met	Gly	Leu	Leu	Glu	Ile	Gly	Arg	Arg	Leu	Ser	Gly	Thr	Asp	Gly	Leu	
	530					535					540					

Pro	Gly	Arg	Thr	Phe	Asp	Ile	Pro	Thr	Leu	Gln	Ala	Thr	Leu	Leu	Arg	
545					550					555					560	
Glu	Ser	Asn	Leu	Thr	Gly	Glu	Met	Tyr	Ala	Ala	Asp	Ala	Ala	Lys	Leu	
				565					570					575		
Cys	Gln	Ser	Ala	Gly	Gly	Ala	Glu	Leu	Gln	Pro	Ala	Cys	Asn	Ala	Leu	
			580					585					590			
Ala	Ala	Trp	Asp	Arg	Arg	Ser	Ser	Gln	Glu	Ser	Arg	Gly	Ala	Ala	Leu	
		595					600					605				
Trp	Arg	Glu	Phe	Trp	Arg	Arg	Ala	Arg	Ala	Ile	Pro	Asn	Val	Tyr	Ala	
	610					615					620					
Val	Pro	Phe	Asp	Pro	Ala	Asp	Pro	Val	Asn	Thr	Pro	Arg	Gly	Leu	Asn	
625					630					635					640	
Thr	Ala	Asp	Pro	Ala	Ala	Gln	Thr	Ala	Leu	Leu	Gly	Ala	Leu	Arg	Glu	
				645					650					655		
Ala	Ala	Ala	Ala	Leu	Thr	Ala	Ala	Gly	Ile	Pro	Phe	Asp	Ala	Pro	Leu	
			660					665					670			
Gly	Glu	Val	Gln	Gly	Val	Val	Arg	Gly	Gly	Asp	Phe	Ile	Ser	Leu	Pro	
		675					680					685				
Gly	Gly	Ala	Glu	Phe	Glu	Gly	Val	Leu	Asp	Lys	Ile	Asp	Phe	Asn	Pro	
	690					695					700					
Leu	Ala	Pro	Gly	Gly	Tyr	Arg	Gly	Val	Val	Gly	Asn	Ala	Ser	Ser	Tyr	
705					710					715					720	
Ile	Gln	Thr	Val	Gly	Phe	Thr	Asp	Ser	Gly	Val	Gln	Ala	Glu	Ala	Val	
				725					730					735		
Leu	Thr	Tyr	Ser	Gln	Ser	Ser	Asn	Pro	Glu	Ser	Pro	Tyr	Phe	Ser	Asp	
			740					745					750			
Gln	Thr	Arg	Leu	Phe	Ser	Arg	Ser	Glu	Trp	Val	Lys	Leu	Pro	Phe	Thr	
		755					760					765				
Gln	Pro	Glu	Ile	Glu	Ala	Asp	Pro	Thr	Arg	Thr	Val	Val	Gln	Leu	Ser	
	770					775					780					
Glu																
785																

<210> 4

<211> 786

<212> PRT

<213> A. utahensis

<400> 4

```

Met Thr Ser Ser Tyr Met Arg Leu Lys Ala Ala Ala Ile Ala Phe Gly
1          5          10          15
Val Ile Val Ala Thr Ala Ala Val Pro Ser Pro Ala Ser Gly Arg Glu
20          25          30
His Asp Gly Gly Tyr Ala Ala Leu Ile Arg Arg Ala Ser Tyr Gly Val
35          40          45
Pro His Ile Thr Ala Asp Asp Phe Gly Ser Leu Gly Phe Gly Val Gly
50          55          60
Tyr Val Gln Ala Glu Asp Asn Ile Cys Val Ile Ala Glu Ser Val Val
65          70          75          80
Thr Ala Asn Gly Glu Arg Ser Arg Trp Phe Gly Ala Thr Gly Pro Asp
85          90          95
Asp Ala Asp Val Arg Thr Thr Ser Ser Thr Gln Ala Ile Asp Asp Arg
100         105         110
Val Ala Glu Arg Leu Leu Glu Gly Pro Arg Asp Gly Val Arg Ala Pro
115         120         125
Cys Asp Asp Val Arg Asp Gln Met Arg Gly Phe Val Ala Gly Tyr Asn
130         135         140
His Phe Leu Arg Arg Thr Gly Val His Arg Leu Thr Asp Pro Ala Cys
145         150         155         160
Arg Gly Lys Ala Trp Val Arg Pro Leu Ser Glu Ile Asp Leu Trp Arg
165         170         175
Thr Ser Trp Asp Ser Met Val Arg Ala Gly Ser Gly Ala Leu Leu Asp
180         185         190
Gly Ile Val Ala Ala Thr Pro Pro Thr Ala Ala Gly Pro Ala Ser Ala
195         200         205
Pro Glu Ala Pro Asp Ala Ala Ala Ile Ala Ala Ala Leu Asp Gly Thr
210         215         220
Ser Ala Gly Ile Gly Ser Asn Ala Tyr Gly Leu Gly Ala Gln Ala Thr
225         230         235         240

```

Val	Asn	Gly	Ser	Gly	Met	Val	Leu	Ala	Asn	Pro	His	Phe	Pro	Trp	Gln	245	250	255
Gly	Ala	Glu	Arg	Phe	Tyr	Arg	Met	His	Leu	Lys	Val	Pro	Gly	Arg	Tyr	260	265	270
Asp	Val	Glu	Gly	Ala	Ala	Leu	Ile	Gly	Asp	Pro	Ile	Ile	Glu	Ile	Gly	275	280	285
His	Asn	Arg	Thr	Val	Ala	Trp	Ser	His	Thr	Val	Ser	Thr	Ala	Arg	Arg	290	295	300
Phe	Val	Trp	His	Arg	Leu	Ser	Leu	Val	Pro	Gly	Asp	Pro	Thr	Ser	Tyr	305	310	315
Tyr	Val	Asp	Gly	Arg	Pro	Glu	Arg	Met	Arg	Ala	Arg	Thr	Val	Thr	Val	325	330	335
Gln	Thr	Gly	Ser	Gly	Pro	Val	Ser	Arg	Thr	Phe	His	Asp	Thr	Arg	Tyr	340	345	350
Gly	Pro	Val	Ala	Val	Val	Pro	Gly	Thr	Phe	Asp	Trp	Thr	Pro	Ala	Thr	355	360	365
Ala	Tyr	Ala	Ile	Thr	Asp	Val	Asn	Ala	Gly	Asn	Asn	Arg	Ala	Phe	Asp	370	375	380
Gly	Trp	Leu	Arg	Met	Gly	Gln	Ala	Lys	Asp	Val	Arg	Ala	Leu	Lys	Ala	385	390	395
Val	Leu	Asp	Arg	His	Gln	Phe	Leu	Pro	Trp	Val	Asn	Val	Ile	Ala	Ala	405	410	415
Asp	Ala	Arg	Gly	Glu	Ala	Leu	Tyr	Gly	Asp	His	Ser	Val	Val	Pro	Arg	420	425	430
Val	Thr	Gly	Ala	Leu	Ala	Ala	Ala	Cys	Ile	Pro	Ala	Pro	Phe	Gln	Pro	435	440	445
Leu	Tyr	Ala	Ser	Ser	Gly	Gln	Ala	Val	Leu	Asp	Gly	Ser	Arg	Ser	Asp	450	455	460
Cys	Ala	Leu	Gly	Ala	Asp	Pro	Asp	Ala	Ala	Val	Pro	Gly	Ile	Leu	Gly	465	470	475
Pro	Ala	Ser	Leu	Pro	Val	Arg	Phe	Arg	Asp	Asp	Tyr	Val	Thr	Asn	Ser	485	490	495
Asn	Asp	Ser	His	Trp	Leu	Ala	Ser	Pro	Ala	Ala	Pro	Leu	Glu	Gly	Phe	500	505	510
Pro	Arg	Ile	Leu	Gly	Asn	Glu	Arg	Thr	Pro	Arg	Ser	Leu	Arg	Thr	Arg	515	520	525
Leu	Gly	Leu	Asp	Gln	Ile	Gln	Gln	Arg	Leu	Ala	Gly	Thr	Asp	Gly	Leu	530	535	540

Pro	Gly	Lys	Gly	Phe	Thr	Thr	Ala	Arg	Leu	Trp	Gln	Val	Met	Phe	Gly	545	550	555	560
Asn	Arg	Met	His	Gly	Ala	Glu	Leu	Val	Arg	Asp	Asp	Leu	Val	Ala	Leu	565	570	575	
Cys	Arg	Arg	Gln	Pro	Thr	Ala	Thr	Ala	Ser	Asn	Gly	Ala	Ile	Val	Asp	580	585	590	
Leu	Thr	Ala	Ala	Cys	Thr	Ala	Leu	Ser	Arg	Phe	Asp	Glu	Arg	Ala	Asp	595	600	605	
Leu	Asp	Ser	Arg	Gly	Ala	His	Leu	Phe	Thr	Glu	Phe	Leu	Ala	Gly	Gly	610	615	620	
Ile	Arg	Phe	Ala	Asp	Thr	Phe	Glu	Val	Thr	Asp	Pro	Val	Arg	Thr	Pro	625	630	635	640
Ala	Pro	Phe	Trp	Asn	Thr	Thr	Asp	Pro	Arg	Val	Arg	Thr	Ala	Leu	Ala	645	650	655	
Asp	Ala	Cys	Asn	Gly	Ser	Pro	Ala	Ser	Pro	Ser	Thr	Arg	Ser	Val	Gly	660	665	670	
Asp	Ile	His	Thr	Asp	Ser	Arg	Gly	Glu	Arg	Arg	Ile	Pro	Ile	His	Gly	675	680	685	
Gly	Arg	Gly	Glu	Ala	Gly	Thr	Phe	Asn	Val	Ile	Thr	Asn	Pro	Leu	Val	690	695	700	
Pro	Gly	Val	Gly	Tyr	Pro	Gln	Val	Val	His	Gly	Thr	Ser	Phe	Val	Met	705	710	715	720
Ala	Val	Glu	Leu	Gly	Pro	His	Gly	Pro	Ser	Gly	Arg	Gln	Ile	Leu	Thr	725	730	735	
Tyr	Ala	Gln	Ser	Thr	Asn	Pro	Asn	Ser	Pro	Trp	Tyr	Ala	Asp	Gln	Thr	740	745	750	
Val	Leu	Tyr	Ser	Arg	Lys	Gly	Trp	Asp	Thr	Ile	Lys	Tyr	Thr	Glu	Ala	755	760	765	
Gln	Ile	Ala	Ala	Asp	Pro	Asn	Leu	Arg	Val	Tyr	Arg	Val	Ala	Gln	Arg	770	775	780	
Gly	Arg															785			

<210> 5

<211> 777

<212> PRT

<213> P. aeruginosa

<400> 5

```

Met Ser Arg Pro Phe Arg Pro Pro Leu Cys Arg Glu Thr Thr Ser Met
1          5          10          15
Gly Met Arg Thr Val Leu Thr Gly Leu Ala Gly Met Leu Leu Gly Ser
20          25          30
Met Met Pro Val Gln Ala Asp Met Pro Arg Pro Thr Gly Leu Ala Ala
35          40          45
Asp Ile Arg Trp Thr Ala Tyr Gly Val Pro His Ile Arg Ala Lys Asp
50          55          60
Glu Arg Gly Leu Gly Tyr Gly Ile Gly Tyr Ala Tyr Ala Arg Asp Asn
65          70          75          80
Ala Cys Leu Leu Ala Glu Glu Ile Val Thr Ala Arg Gly Glu Arg Ala
85          90          95
Arg Tyr Phe Gly Ser Glu Gly Lys Ser Ser Ala Glu Leu Asp Asn Leu
100         105         110
Pro Ser Asp Ile Phe Tyr Ala Trp Leu Asn Gln Pro Glu Ala Leu Gln
115         120         125
Ala Phe Trp Gln Ala Gln Thr Pro Ala Val Arg Gln Leu Leu Glu Gly
130         135         140
Tyr Ala Ala Gly Phe Asn Arg Phe Leu Arg Glu Ala Asp Gly Lys Thr
145         150         155         160
Thr Ser Cys Leu Gly Gln Pro Trp Leu Arg Ala Ile Ala Thr Asp Asp
165         170         175
Leu Leu Arg Leu Thr Arg Arg Leu Leu Val Glu Gly Gly Val Gly Gln
180         185         190
Phe Ala Asp Ala Leu Val Ala Ala Ala Pro Pro Gly Ala Glu Lys Val
195         200         205
Ala Leu Ser Gly Glu Gln Ala Phe Gln Val Ala Glu Gln Arg Arg Gln
210         215         220
Arg Phe Arg Leu Glu Arg Gly Ser Asn Ala Ile Ala Val Gly Ser Glu
225         230         235         240

```


Arg Ser Ala Asp Gly Lys Gly Met Leu Leu Ala Asn Pro His Phè Pro
 245 250 255
 Trp Asn Gly Ala Met Arg Phe Tyr Gln Met His Leu Thr Ile Pro Gly
 260 265 270
 Arg Leu Asp Val Met Gly Ala Ser Leu Pro Gly Leu Pro Val Val Asn
 275 280 285
 Ile Gly Phe Ser Arg His Leu Ala Trp Thr His Thr Val Asp Thr Ser
 290 295 300
 Ser His Phe Thr Leu Tyr Arg Leu Ala Leu Asp Pro Lys Asp Pro Arg
 305 310 315 320
 Arg Tyr Leu Val Asp Gly Arg Ser Leu Pro Leu Glu Glu Lys Ser Val
 325 330 335
 Ala Ile Glu Val Arg Gly Ala Asp Gly Lys Leu Ser Arg Val Glu His
 340 345 350
 Lys Val Tyr Gln Ser Ile Tyr Gly Pro Leu Val Val Trp Pro Gly Lys
 355 360 365
 Leu Asp Trp Asn Arg Ser Glu Ala Tyr Ala Leu Arg Asp Ala Asn Leu
 370 375 380
 Glu Asn Thr Arg Val Leu Gln Gln Trp Tyr Ser Ile Asn Gln Ala Ser
 385 390 395 400
 Asp Val Ala Asp Leu Arg Arg Arg Val Glu Ala Leu Gln Gly Ile Pro
 405 410 415
 Trp Val Asn Thr Leu Ala Ala Asp Glu Gln Gly Asn Ala Leu Tyr Met
 420 425 430
 Asn Gln Ser Val Val Pro Tyr Leu Lys Pro Glu Leu Ile Pro Ala Cys
 435 440 445
 Ala Ile Pro Gln Leu Val Ala Glu Gly Leu Pro Ala Leu Gln Gly Gln
 450 455 460
 Asp Ser Arg Cys Ala Trp Ser Arg Asp Pro Ala Ala Ala Gln Ala Gly
 465 470 475 480
 Ile Thr Pro Ala Ala Gln Leu Pro Val Leu Leu Arg Arg Asp Phe Val
 485 490 495
 Gln Asn Ser Asn Asp Ser Ala Trp Leu Thr Asn Pro Ala Ser Pro Leu
 500 505 510
 Gln Gly Phe Ser Pro Leu Val Ser Gln Glu Lys Pro Ile Gly Pro Arg
 515 520 525
 Ala Arg Tyr Ala Leu Ser Arg Leu Gln Gly Lys Gln Pro Leu Glu Ala
 530 535 540

Lys Thr Leu Glu Glu Met Val Thr Ala Asn His Val Phe Ser Ala Asp
 545 550 555 560
 Gln Val Leu Pro Asp Leu Leu Arg Leu Cys Arg Asp Asn Gln Gly Glu
 565 570 575
 Lys Ser Leu Ala Arg Ala Cys Ala Ala Leu Ala Gln Trp Asp Arg Gly
 580 585 590
 Ala Asn Leu Asp Ser Gly Ser Gly Phe Val Tyr Phe Gln Arg Phe Met
 595 600 605
 Gln Arg Phe Ala Glu Leu Asp Gly Ala Trp Lys Glu Pro Phe Asp Ala
 610 615 620
 Gln Arg Pro Leu Asp Thr Pro Gln Gly Ile Ala Leu Asp Arg Pro Gln
 625 630 635 640
 Val Ala Thr Gln Val Arg Gln Ala Leu Ala Asp Ala Ala Ala Glu Val
 645 650 655
 Glu Lys Ser Gly Ile Pro Asp Gly Ala Arg Trp Gly Asp Leu Gln Val
 660 665 670
 Ser Thr Arg Gly Gln Glu Arg Ile Ala Ile Pro Gly Gly Asp Gly His
 675 680 685
 Phe Gly Val Tyr Asn Ala Ile Gln Ser Val Arg Lys Gly Asp His Leu
 690 695 700
 Glu Val Val Gly Gly Thr Ser Tyr Ile Gln Leu Val Thr Phe Pro Glu
 705 710 715 720
 Glu Gly Pro Lys Ala Arg Gly Leu Leu Ala Phe Ser Gln Ser Ser Asp
 725 730 735
 Pro Arg Ser Pro His Tyr Arg Asp Gln Thr Glu Leu Phe Ser Arg Gln
 740 745 750
 Gln Trp Gln Thr Leu Pro Phe Ser Asp Arg Gln Ile Asp Ala Asp Pro
 755 760 765
 Gln Leu Gln Arg Leu Ser Ile Arg Glu
 770 775

<210> 6

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Forward Primer for the QsbA gene

<400> 6

cgtggatcca tgatgcagga ttcgccgctg cgc

33

<210> 7

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Reverse Primer for the QsbA gene

<400> 7

cgcgattca ccggcagccc tcatgcgaca ac

32

INTERNATIONAL SEARCH REPORT

International Application No

PCT/SG 02/00011

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N9/80 C12N15/57 A01K67/027 A61K38/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBL, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE SWISS-PROT 'Online! EBI-SBI; 1 May 2000 (2000-05-01) WHITE ET AL.: "Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1; Science 286:1571-1577 (1999)" retrieved from SWISS-PROT Database accession no. Q9RYQ4 XP002208348 "Aculeacin A acylase from Deinococcus radiodurans R1; 53,316% identity with SEQ ID NO: 2 in 769 aa overlap". abstract</p> <p style="text-align: center;">--- -/--</p>	4-6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

14 August 2002

Date of mailing of the international search report

02/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Ury, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/SG 02/00011

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! EBI; 23 November 1999 (1999-11-23) WHITE ET AL.: "Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1; Science 286:1571-1577 (1999)" Database accession no. AE001836 XP002208349 "CDS complement (53991..56348): Encoding Aculeacin A acylase from Deinococcus radiodurans R1: 62,025% identity with SEQ ID NO: 1 in 1817 nt overlap".</p>	2
X	<p>WO 01 98214 A (NOVOZYMES BIOTECH INC) 27 December 2001 (2001-12-27) the whole document</p>	2,4-6, 10-20
Y	<p>same citations</p>	2,4-6, 10-20
Y	<p>LEADBETTER JARED R ET AL: "Metabolism of acyl-homoserine lactone quorum-sensing signals by <i>Variovorax paradoxus</i>." JOURNAL OF BACTERIOLOGY, vol. 182, no. 24, December 2000 (2000-12), pages 6921-6926, XP002208346 ISSN: 0021-9193 cited in the application abstract; figure 7</p>	2,4-6, 10,20
Y	<p>LEADBETTER JARED R: "Quieting the raucous crowd" NATURE, vol. 411, 14 June 2001 (2001-06-14), pages 748-749, XP002208347 Figure 7 the whole document</p>	2,4-6, 10-20
A	<p>DONG YI-HU ET AL: "AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of <i>Erwinia carotovora</i>" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 97, no. 7, 28 March 2000 (2000-03-28), pages 3526-3531, XP002166712 ISSN: 0027-8424 cited in the application abstract</p>	1-20
	<p>--- -/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No
PCT/SG 02/00011

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DONG YI-HU ET AL.: "Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase"</p> <p>NATURE, vol. 411, 14 June 2001 (2001-06-14), pages 813-817, XP001093866 cited in the application abstract</p> <p>-----</p>	1-20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/SG 02/00011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0198214 A	27-12-2001	AU 6993901 A WO 0198214 A1	02-01-2002 27-12-2001
<hr/>			